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Abstract and Keywords 
Abstract 
This dissertation presents two separate chapters within the broad area of synthetic organic 
chemistry. The first chapter describes the annelation chemistry of donor-acceptor (DA) 
cyclopropanes and cyclobutanes for the synthesis of heterocycles. The Yb(OTf)3-catalyzed 
[4+2] cycloaddition between DA cyclobutanes and nitrosoarenes facilitated the synthesis of 
tetrahydro-1,2-oxazines in good to excellent yields as single diastereomers. Additionally, an 
unexpected deoxygenation occurred with electron-rich nitrosoarenes under MgI2-catalysis 
that afforded pyrrolidine products. The GaCl3-catalyzed [4+2] cycloaddition of DA 
cyclobutanes and cis-diazenes provided hexahydropyridazine derivatives in good to excellent 
yields as single diastereomers. Furthermore, a procedure to make spiroketals from the [4+2] 
cycloaddition of spirocyclic DA cyclobutanes and aldehydes is also disclosed. Lastly, a 
cascade reaction of DA cyclopropanes with nitrosoarenes is discussed. The reaction results in 
formation of tetrahydro-1,2-oxazine instead of normal cycloadduct isoxazolidine via a 
tandem ring opening, elimination, and cycloaddition sequence. A detailed discussion of the 
results along with associated mechanisms is presented. 
The second chapter describes multiple strategies applied towards the synthesis of the 
prodigiosin alkaloid streptorubin B. The key aspect of the strategies is utilization of our 
group developed [3+2] cycloaddition between DA cyclopropanes and nitriles. An overview 
of this methodology and its application towards the synthesis of natural products is presented. 
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Preface 
It is every synthetic organic chemist’s vision to make a complex product from trivial starting 
materials in a manner that absolutely controls regio- and stereoselectivity. Intermolecular 
cycloaddition chemistry offers a tool which assists in turning this vision into a reality. One 
manner of facilitating cycloaddition chemistry is through exploitation of ring strain in 
carbocycles. In this regard cyclopropanes, typically bearing vicinally substituted electron 
donating and electron accepting groups, suitably named as donor-acceptor (DA) 
cyclopropanes, are extensively studied. While this area continues to mature, reports on 
extending similar synthetic transformations to the homologous cyclobutanes are 
comparatively limited. Recently, the Pagenkopf group has begun exploring application of 
DA cyclobutanes in cycloaddition chemistry. While exploring this reaction space in 
collaboration with co-workers, new modes of reactivity were discovered.  
 The first chapter of this thesis will discuss several novel reactions of DA 
cyclobutanes and cyclopropanes. We have disclosed the first example of a [4+2] 
cycloaddition between DA cyclobutanes and nitrosoarenes. The reaction proceeds well with 
electron neutral and deficient nitrosoarenes, but electron-rich nitrosoarenes required a 
stronger Lewis acid, MgI2. Interestingly, with electron-rich nitrosoarenes, a deoxygenation 
process was observed resulting in the formation of pyrrolidines from tetrahydro-1,2-oxazines 
in MgI2 conditions. We have also developed the first example of a [4+2] cycloaddition 
between DA cyclobutanes and cis-diazenes. The reaction proceeds smoothly with alkoxy 
activated cyclobutanes as well as aryl activated cyclobutanes to form hexahydropyridazines 
in good to excellent yields. Furthermore, a procedure to make spiroketals from [4+2] 
cycloaddition of spirocyclic DA cyclobutanes with aldehydes was also developed. In 
 xxiv 
 
addition, we have discovered a cascade reaction of DA cyclopropanes with nitrosoarenes to 
form tetrahydro-1,2-oxazines. The cascade reaction proceeds through a ring opening of DA 
cyclopropane, followed by fragmentation to a nitrone intermediate and cycloaddition with 
second equivalent of DA cyclopropane to generate the tetrahydro-1,2-oxazines as single 
diastereomers in good to excellent yields. 
The second chapter discusses the different strategies applied towards the synthesis of 
the biologically active prodigiosin alkaloid streptorubin B, using our group's [3+2] 
cycloaddition of DA cyclopropanes and nitriles. 
It is my sincere hope that the reader, through the results discussed throughout the 
thesis, can arrive at a better understanding of the chemistry of DA cyclopropanes and 
cyclobutanes. 
 
-Naresh Vemula 
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1 Chapter 1. New Chemistry of Donor-Acceptor Cycloalkanes 
This chapter discusses new reactions of DA cyclopropanes and cyclobutanes. In 
collaboration with fellow graduate student Andrew C. Stevens (Ph.D. 2013) and 
undergrad Tyler B. Schon (B.Sc. 2011), we have developed the first example of a [4+2] 
cycloaddition of DA cyclobutanes and nitrosoarenes. In an attempt to extend this 
methodology to DA cyclopropanes, we discovered a novel cascade reaction that 
ultimately generated tetrahydro1,2-oxazines. In collaboration with fellow graduate 
student Tristan Chidley, we studied the mechanism through crossover experiments. The 
first example of a [4+2] cycloaddition of DA cyclobutanes and cis-diazenes was also 
developed, in collaboration with Tristan Chidley. Additionally, a procedure to make 
spiroketals from spirocyclic DA cyclobutanes was also developed.  
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1.1 Introduction 
1.1.1 General Introduction to Cyclopropanes and Cyclobutanes 
Cyclopropanes and cyclobutanes are highly strained carbocycles.1 The strain in any 
cyclic compound is a composite of three types of individual strain: transannular strain 
due to Van der Waals interactions between atoms across the ring, torsional strain (also 
called as Pitzer strain) due to eclipsing conformations between adjacent atoms, and angle 
strain (also called as Baeyer strain) due to distorted bond angles from the ideal for a given 
hybridization.2 While transannular strain is predominant in medium-sized rings (see, 
section 2.4), cyclopropanes, and cyclobutanes experience severe Baeyer and Pitzer 
strains. Although, these two strained carbocycles have similar ring strain (27.5 kcal/mol 
for cyclopropane and 26.3 kcal/mol for cyclobutane), there are notable differences in 
their structures.3 While cyclopropane has 60° C-C-C bond angles, similar to a planar 
equatorial triangle, cyclobutanes adopt a puckered conformation to reduce the Pitzer 
strain, but at the expense of Baeyer strain, and thus the C-C-C bond angle is <90° (Figure 
1-1). Also the strain energy in cyclobutane is distributed over four carbons (6.6 
kcal/mol/C–C bond) compared to three carbons in case of cyclopropane (9.2 kcal/mol/C-
C bond).  
 
Figure 1-1. Pictorial representation of puckering conformation of cyclobutane. 
1.1.2 Donor-Acceptor Cyclopropanes 
The reactivity of the cyclopropanes can be predictable by the substitution pattern around 
the ring (Figure 1-2). Electron-donating groups (D, such as amino or alkoxy) activate the 
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cyclopropane and increase its ability to react with electrophiles (eq 1, Figure 1-2). 
Likewise, electron-acceptor groups (A, such as carbonyl or nitro) increase the 
electrophilicity of the cyclopropane ring allowing homo-Michael type additions (eq 2, 
Figure 1-2).   Interestingly, when both electron donating and electron-accepting groups 
are vicinally substituted, the strained C-C bond becomes polarized through a push-pull 
mechanism resulting in a 1,3-zwitterionic intermediate.4 This can be trapped by 
appropriate dipolarophiles, such as aldehydes or nitrones, to access annulated compounds 
(eq 3, Figure 1-2). These three types of substitution patterns on cyclopropanes, classifies 
them into three categories, namely, donor cyclopropanes, acceptor cyclopropanes, and 
donor-acceptor (DA) cyclopropanes.5  
 
Figure 1-2. Modes of cyclopropane reactivity. 
 Substituent-activated chemistry of cyclopropanes was pioneered by the groups of 
Wenkert (on donor cyclopropanes),6  Danishefsky (on acceptor cyclopropanes),7 and 
Reissig (on DA cyclopropanes).9a-b The first formal cycloaddition of DA cyclopropanes 
was reported by Reissig (Scheme 1-1).8 In this seminal report, Reissig reported the 
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annulation of DA cyclopropane 1-1 with benzophenone (1-2), mediated by TiCl4, which 
resulted in tetrahydrofuran 1-3 in almost quantitative yield. 
 
Scheme 1-1. First cycloaddition of DA cyclopropane 1-1 with benzophenone (1-2). 
Since this seminal report, a plethora of discoveries have been published in this 
area.9  Two of the finest reactions in this field relevant to this thesis are, the [3+2] 
cycloaddition of DA cyclopropanes with nitriles10 (which is reviewed in section 2.3) and 
the [3+3] cycloaddition of DA cyclopropanes with nitrones.11  
1.1.2.1 The [3+3] Cycloaddition of Nitrones and Donor-Acceptor Cyclopropanes 
1.1.2.1.1 The Reaction Discovery and Development 
The first example of a [3+3] cycloaddition of DA cyclopropanes with nitrones12 was 
reported by Kerr and Young in 2003.11a The reaction of an aldehyde-derived nitrone 1-5 
with DA cyclopropane 1-4 in presence of catalytic Yb(OTf)3 resulted in tetrahydro-1,2-
oxazine 1-6 in good to excellent yields and diastereoselectivity (Scheme 1-2).  
 
Scheme 1-2. The [3+3] cycloaddition of DA cyclopropanes and nitrones. 
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 In 2004, Kerr and co-workers further developed this reaction to encompass 
unstable nitrones via a three-component coupling of hydroxylamines, aldehydes, and DA 
cyclopropanes.11c This multicomponent reaction allows the formation of a diverse array 
of tetrahydro-1,2-oxazines, which can then be transformed into congeners of FR900482 
(similar to Scheme 1-5). 
In 2005, Sibi and co-workers reported an asymmetric variant of this cycloaddition 
using bisoxazoline ligand 1-10 catalyzed by Ni(ClO4)2 (Scheme 1-3).
11d Excellent yields 
and enantiomeric excess was observed, but kinetic resolution remained elusive while 
using racemic cyclopropanes.   
 
Scheme 1-3. Sibi’s asymmetric [3+3] cycloaddition of DA cyclopropanes and nitrones. 
 A few years later, in 2007, Tang and co-workers addressed the kinetic resolution 
problem using trisoxazoline ligand 1-14 in the Ni(ClO4)2–catalyzed asymmetric [3+3] 
cycloaddition of nitrones with DA cyclopropanes.11g As shown in the example in Scheme 
1-4, both enantiomers of tetrahydro-1,2-oxazine 1-13 can be prepared from racemic DA 
cyclopropane 1-11 by either a direct cycloaddition with nitrone 1-12 in the presence of 
catalytic 1-14/Ni(ClO4)2 (eq 1, Scheme 1-4) or a 1-14/Ni(ClO4)2-catalyzed kinetic 
resolution followed by cycloaddition with nitrone  1-12 (eq 2, Scheme 1-4).  
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Scheme 1-4. Kinetic resolution of racemic DA cyclopropane for the synthesis of both 
enantiomers of tetarahydro-1,2-oxazine. 
1.1.2.1.2 Application in Target-oriented Synthesis 
Although, the tetrahydro-1,2-oxazine structure is not abundant in nature, the core can be 
found in a few natural products13 as well as in pharmaceutical drugs14 (Figure 1-3).   
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Figure 1-3. Representative examples of tetrahydro-1,2-oxazine core in natural products 
and pharmaceutical drugs. 
Although multiple methods exist for the synthesis of tetrahydro-1,2-oxazines,15 
the [3+3] cycloaddition allows for the rapid generation of structural complexity from 
simple starting materials. For instance, in the same methodology paper,11a the authors 
demonstrated the utility of this elegant reaction in the synthesis of tricyclic skeleton of 
the antitumor agent FR-900482 (1-18).16 As shown in Scheme 1-5, nitrone 1-19 
underwent a [3+3] cycloaddition with DA cyclopropane 1-20 to afford tetrahydro-1,2-
oxazine 1-21  in 77% yield. In a similar manner to Danishefsky’s synthesis,16b oxazine 1-
21 was converted into the desired tricyclic core 1-22 in 73% yield. 
 
Scheme 1-5. Synthesis of the FR-900482 skeleton via [3+3] cycloaddition. 
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In 2006, Kerr and Carson showcased the [3+3] cycloaddition of nitrones with DA 
cyclopropanes, in their elegant total synthesis of a securinega alkaloid, (+)-phyllantidine 
(1-15, Scheme 1-6).11e The tetrahydro-1,2-oxazine core structure of (+)-phyllantidine (1-
15) was efficiently accessed from a three component coupling of aldehyde 1-23, 
hydroxylamine 1-24, and enantiopure DA cyclopropane (R)-1-20 in 86% yield (Scheme 
1-6). Oxazine 1-25 was then converted into the natural product (+)-phyllantidine (1-15) 
in a series of transformations. Thus the synthesis of (+)-phyllantidine was achieved in 6% 
overall yield over 12 linear steps from DA cyclopropane (R)-1-20.  
 
Scheme 1-6. Total synthesis of (+)-phyllantidine via [3+3] cycloaddition. 
 Reissig and co-workers demonstrated the application of tetrahydro-1,2-oxazines 
in synthesis of pyrrolidines via a reductive cleavage of the N-O bond, followed by 
cyclization.17 Kerr and co-workers applied this strategy on tetrahydro-1,2-oxazine 1-28 
accessed from a three component coupling of aldehyde 1-27, hydroxylamine 1-24, and 
enantiopure DA cyclopropane (R)-1-26 for the enantioselective synthesis of manzamine 
alkaloid (+)-nakadomarin A (1-32, Scheme 1-7).18 
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Scheme 1-7. Enantioselective synthesis of (+)-nakadomarin A via [3+3] cycloaddition of 
nitrone and DA cyclopropane. 
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As shown in Scheme 1-7 the three component coupling of aldehyde 1-27, 
hydroxylamine 1-24, and enantiopure DA cyclopropane (R)-1-26 (derived from D-
mannose) gave oxazine 1-28 in 87% yield. The oxazine 1-28 was then converted into an 
advanced intermediate 1-29 through a series of transformations. Hydrogenolytic cleavage 
of the N-O bond of oxazine 1-29 gave the amino alcohol 1-30, which was selectively 
converted into O-mesylate and treated with base to afford pyrrolidine 1-31 in a 65% yield 
over three steps with inversion of configuration at reaction center. The pyrrolidine 1-31 
was then carried on to (+)-nakadomarin A through a series of reactions. Thus the 
synthesis of (+)-nakadomarin A was achieved in 23 steps from DA cyclopropane (R)-1-
26. 
In 2012, Kerr and co-workers extended the applications of tetrahydro-1,2-
oxazines towards synthesis Atorvastatin pyrrole (1-38, Scheme 1-8).19 As described in 
Scheme 1-8, the synthesis began with the [3+3] cycloaddition of nitrone 1-33 and DA 
cyclopropane 1-34 to afford oxazine 1-35 in 60% yield. Tsuji dehydrocarbonylation on 
the oxazine 1-35 provided the enolate 1-36 which was immediately treated with DBU to 
obtain pyrrole 1-37 in 70% yield over two steps.20 The pyrrole 1-37 was then converted 
into an advanced intermediate 1-38 through a series of transformations. Thus conversion 
of tetrahydro-1,2-oxazines to pyrroles was showcased in synthesis of Atorvastatin pyrrole 
(1-38).21 
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Scheme 1-8. Synthesis of Atorvastatin pyrrole 1-38 via [3+3] cycloaddition of nitrone 
and DA cyclopropane. 
In summary, the [3+3] cycloaddition of nitrones and DA cyclopropanes has 
proven to be an excellent method to construct tetrahydro-1,2-oxazines. The efficiency of 
the reaction has been well demonstrated in synthesis of natural products (+)-phyllantidine 
(1-15) and (+)-nakadomarin A (1-32). The tetrahydro-1,2-oxazines were also 
manipulated to congeners of pharmaceutical drug FR-900482 (1-18) and Atorvastatin 
pyrrole (1-38). 
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1.1.3 Donor-Acceptor Cyclobutanes  
While the chemistry of DA cyclopropanes continues to mature, reports extending similar 
synthetic transformations to the homologous cyclobutanes are comparatively limited 
(Figure 1-4).22 
 
Figure 1-4. Potential reactivity of DA cyclobutanes with generic dipolarophile X=Y. 
1.1.3.1 Seminal Reports in DA Cyclobutane Chemistry 
Even though the de Mayo reaction, in which the transient cyclobutane 1-42 
undergoes a rapid ring opening to give 1,5-dicarbonyl compound 1-43, has been known 
in the literature since the 1960s (Scheme 1-9),23 attempts to explore the reactivity of DA 
cyclobutanes was not made until early 1990s. 
 
Scheme 1-9. Ring opening of the transient cyclobutane 1-42 in the de Mayo reaction. 
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The first report of formal cycloaddition of DA cyclobutanes was disclosed by 
Saigo and co-workers in 1991.24  In this work, amino-activated DA cyclobutanes 1-44 
underwent [4+2] cycloadditions with carbonyl compounds 1-45 to generate 
tetrahydropyrans 1-46, albeit with low diastereoselectivity and modest yield (Scheme 
1-10). 
 
Scheme 1-10. The [4+2] cycloaddition of amino-activated DA cyclobutanes with 
carbonyl compounds. 
A few years later, in 1997, Suzuki and co-workers observed a [4+2] cycloaddition 
of highly activated DA cyclobutane 1-47 with 2-oxazoline (1-48) without the need for a 
catalyst (Scheme 1-11).25  
 
Scheme 1-11. The [4+2] cycloaddition of DA cyclobutane 1-47 with 2-oxazoline (1-48). 
The field remained relatively dormant for a decade, until 2008, when Matsuo and 
co-workers observed a conceptually similar [4+2] cycloaddition26 with 3-
alkoxycyclobutanones 1-50 and carbonyl compounds 1-52 (Scheme 1-12).27 
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Scheme 1-12. The [4+2] cycloaddition of 3-alkoxycyclobutanones 1-50 with carbonyl 
compounds 1-52. 
Shortly after the disclosure by Matsuo, the first catalytic cycloaddition of DA 
cyclobutanes with aldehydes that possessed a significantly broad substrate scope was 
reported by the research groups of Johnson28 and of Christie and Pritchard.31 The [4+2] 
cycloaddition with aldehydes 1-55 was found to proceed under mild conditions with good 
to excellent yields. In contrast to the work conducted by Saigo (Scheme 1-10), the DA 
cyclobutanes in these reports used carbon-based electron-donating groups (aryl, vinyl or 
cobalt-alkyne complex) and 1,1-diester substituents as the electron-accepting groups 
(Scheme 1-13). 
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Scheme 1-13. The [4+2] cycloaddition of carbon-activated cyclobutane-1,1-
dicarboxylates 1-54 with aldehydes 1-55. 
Johnson found that Sc(OTf)3 was able to catalyze the cycloaddition with loadings 
as low as 2 mol % (eq 1, Scheme 1-13).28  The cycloaddition was highly 
diastereoselective for the 2,6-cis-diastereomer with the majority of the aryl aldehydes 
investigated, but when cinnamaldehyde was used the diastereoselectivity dropped to 
77:23, possibly due to the slow reactivity.29  The group was able to encompass aliphatic 
aldehydes with the more reactive and bulky Lewis acid, MADNTf2.
30  
The work by Christie and Pritchard reported a similar reactivity of cyclobutanes 
with a cobalt–alkyne complex as an electron-donor and 1,1-diesters as electron-acceptors 
(eq 2, Scheme 1-13).31  The group also found Sc(OTf)3 as the best catalyst for this 
transformation. Most of the aryl aldehydes and other electron-rich aldehydes underwent 
the cycloaddition in good to excellent yields, forming the tetrahydropyran products as 
single diastereomers. When aliphatic aldehydes were used, the diastereoselectivity 
significantly dropped to 20-23% de. 
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It became apparent from the preceding examples that having 1,1-diesters as 
electron-acceptors enhanced the reactivity as well as the diastereoselectivity in 
cycloadditions as compared to a monoester.  Inspired by these seminal reports and 
ongoing interest of Pagenkopf group (referred hereinafter as “we” or “our”) in alkoxy-
activated cyclopropane chemistry,32 we were motivated to investigate the reactivity 
alkoxy-activated cyclobutane-1,1-dicarboxylates (AACDs). 
1.1.3.2 Synthesis of Alkoxy-activated Cyclobutane-1,1-dicarboxylates 
At the outset of our work, only two literature methods were available for the synthesis of 
AACDs (Scheme 1-14). 
 
Scheme 1-14. Literature methods for the synthesis of AACDs. 
The use of a Michael induced ring closure of acyclic substrates (eq 1, Scheme 
1-14) was not selected as a preparative route as it offers limited control over the 
stereochemistry, and requires multiple steps.33  On the other hand, a ZnBr2-promoted 
[2+2] annulation reported by Roberts in 1986 appeared much more promising since the 
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required alkyl enol ethers are commercially available or can be readily prepared, and the 
methylidene malonates can be easily accessed through Knoevenagel condensation (eq 2, 
Scheme 1-14).34  Although this procedure could be utilized to prepare a number of 
AACDs containing 1,1-di-tert-butyl esters, this methodology could not be extended to 
prepare the more reactive ethyl- or methyl-substituted AACDs.35 To circumvent this 
challenge, a catalyst screening was explored, and it was revealed Yb(OTf)3 as the best 
catalyst for this [2+2] cycloaddition.  With the optimized conditions in hand, the scope of 
the cyclobutane synthesis was explored (Table 1-1).38 
Table 1-1. The synthesis of AACDs. 
 
 
A range of cyclic and acyclic enol ethers were found to undergo cycloaddition 
with a variety of dialkyl methylidene malonates to generate AACDs in good to excellent 
yields as single diastereomers (1-67a-1-67g, Table 1-1). In addition to enol ethers, 
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electron-rich styrenes were also found to undergo efficient cycloaddition to yield AACDs 
in good yields (1-67h-1-67k, Table 1-1). With the AACDs at hand, the reactivity was 
explored with a variety of dipolarophiles 
1.1.3.3 Reactivity of Alkoxy-activated Cyclobutane-1,1-dicarboxylates 
1.1.3.3.1 The [4+2] Cycloaddition of AACDs with Aldehydes 
Interestingly, initial investigations established that Yb(OTf)3, which was used for the 
synthesis of AACDs (Table 1-1), was also a competent catalyst for the [4+2] 
cycloaddition with aldehydes.36 A wide range of aldehydes were found to undergo 
cycloadditions with AACDs in good to excellent yields, forming tetrahydropyrans as 
single diastereomers (Table 1-2). Aryl, heteroaryl, vinyl, and alkynyl aldehydes 
underwent smooth cycloadditions to afford tetrahydropyrans 1-69 in good to excellent 
yields (1-69a-1-69j). Finally, aliphatic aldehydes were also found to engage in 
cycloadditions, but only modest yields were observed (1-69k-1-69m). 
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Table 1-2. The [4+2] cycloaddition of AACDs with aldehydes. 
 
1.1.3.3.2 The [4+2] Cycloaddition of AACDs with Imines 
With the above example, the feasibility of cycloaddition chemistry with AACDs was 
confirmed. Our interest then shifted to further explore other possible dipolarophiles 
which could lead to desirable or novel structural architectures. Although imines were 
excellent dipolarophiles in cycloadditions with DA cyclopropanes,37 their reactivity with 
DA cyclobutanes was unexplored.  Thus, we set out to investigate the reactivity of imines 
with AACDs.  Upon exposure of cyclobutane 1-67 and imine 1-70 (prepared in situ) to 
catalytic Yb(OTf)3 at -50 °C, a mixture of bicyclic piperidine 1-71 and piperideine 1-72 
were formed (Table 1-3).38 In order to converge on the piperideine product 1-72, the 
reaction was simply warmed to rt after the cyclobutane was consumed.39 Electron-rich 
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styrene derived cyclobutanes were also found to undergo cycloaddition to afford 
exclusive 2,6-trans-piperidines, but longer reaction times were necessary (1-71a-1-71d).  
Table 1-3. The [4+2] cycloaddition of AACDs with imines. 
 
1.1.3.3.3 The [4+3] Cycloaddition of AACDs with Nitrones 
Having successfully expanded the reactivity of AACDs to imines, our interest turned to 
explore 3-atom dipolarophiles. Nitrones have previously been reported as excellent 
dipolarophiles in cycloadditions with DA cyclopropanes (see Section 1.1.2.1).  Given this 
precedent, we investigated the reactivity of nitrones with AACDs.  
After brief optimization studies, 5 mol % Yb(OTf)3 was determined to be the best 
catalyst for this cycloaddition.40 Interestingly, cis-diastereomers were formed as 
thermodynamic products when the reaction was performed at rt; however a 
diastereomeric mixture containing significant amounts of the kinetic trans-diastereomer 
could be obtained at lower temperatures (Table 1-4).41  Additionally, when electron-
deficient nitrone 1-73d was used, an inseparable third diastereomer was observed (entry 
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4),42 however, all three diastereomers would eventually converge to the single 
thermodynamic product. The heterocycle, 1,2-oxazepanes, are intriguing and unique 
structural motifs that are not naturally occurring, but they do display interesting 
antiviral43  and antiproliferative44  activity. 
Table 1-4. The [4+3] cycloaddition of AACDs with nitrones. 
 
entry 1,2-oxazepane 
at 0 °C 
yield (cis:trans:3rd) 
at rt 
yield (cis) 
1 1-73a: Ar = C6H5 91% (31:69) 76% 
2 1-73b: Ar = 4-C6H4Cl 82% (29:71) 73% 
3 1-73c: Ar = 4-C6H4OMe 88% (37:63) 74% 
4 1-73d: Ar = 4-C6H4CN 95% (15:57:27) 76% 
 
1.1.3.3.4 BF3·OEt2-promoted Reaction of AACDs with Terminal Alkynes 
Intrigued with the success of above discussed cycloadditions, we were then interested to 
study an all carbon dipolarophile, such as the alkynes. Terminal alkynes have previously 
been reported to undergo efficient [3+2] cycloadditions with DA cyclopropanes.45  After 
a multitude of unsuccessful attempts, it was discovered that stoichiometric BF3·OEt2 
could promote the reaction to generate a peculiar 2,3-dihydrooxepine structure 1-76. This 
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structure originated from an addition/rearrangement sequence via a highly strained 
bicyclic intermediate 1-79 (Scheme 1-15).46 
 
Scheme 1-15. BF3·OEt2-promoted reaction of AACDs with terminal alkynes. 
Only arylacetylenes with electron-neutral and moderately electron-rich 
substituents proceeded through a productive reaction manifold, albeit in low yields (1-
76a-1-76e, Scheme 1-15). Substrates with strong electron-donating substituents rapidly 
polymerized upon exposure to BF3·OEt2, whereas, electron-deficient alkynes failed to 
react.47 Interestingly, when silyloxy substituted phenylacetylene 1-75f was used, the 
reaction resulted in the expected [4+2] cycloadduct 1-80f (Scheme 1-16). This was the 
only case we observed cycloaddition instead of rearrangement, which could be due to the 
increased bulk on the aryl ring inhibiting the polymerization and/or rearrangement. 
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Scheme 1-16. The [4+2] cycloaddition of alkyne 1-75f with AACD 1-67b. 
1.1.3.4 Additional Cyclobutane-1,1-dicarboxylates 
In recent years, several other groups have reported interesting cycloadditions of DA 
cyclobutanes. Most recently, Tang and co-workers reported the enantioselective [4+3] 
cycloaddition of DA cyclobutanes and nitrones (Scheme 1-17).48  While contributing the 
first enantioselective variant, the group also added several new DA cyclobutanes to the 
library. 
 
Scheme 1-17. Enantioselective [4+3] cycloaddition of DA cyclobutanes 1-81 with 
nitrones 1-83. 
Waser and co-workers enhanced the family of DA cyclobutanes by developing a 
Fe(III)-catalyzed [2+2] cycloaddition of enimides 1-85 and alkylidene malonates 1-86 to 
access amino-activated cyclobutane-1,1-dicarboxylates 1-87 (Scheme 1-18).49 
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Scheme 1-18. Waser’s synthesis of amino-activated cyclobutane-1,1-dicarboxylates. 
The group also disclosed the reactivity of these DA cyclobutanes with aldehydes 
and silyl enolethers (Scheme 1-19).50  Interestingly, in the reaction with aldehydes 1-88 
(eq 1, Scheme 1-19), the less substituted DA cyclobutanes 1-87 (R2 = R3 = H) could be 
activated with Sc(OTf)3, but the more substituted 1-87 (R
2 = R3 ≠ H) required 
FeCl3·Al2O3. More interestingly, thymine- or fluorouracil-substituted cyclobutanes were 
also found to undergo cycloaddition with aldehydes under Hf(OTf)4 catalysis to access 
six-membered ring carbonucleoside analogues. In reaction with silyl enolethers, only less  
 
Scheme 1-19. [4+2] cycloadditions of amino-activated cyclobutane-1,1-dicarboxylates 1-
87 with aldehydes 1-88 and silyl enolethers 1-90. 
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substituted DA cyclobutanes 1-87 (R2 = R3 = H) were found to undergo cycloadditions 
(eq 2, Scheme 1-19).  
The first intramolecular cycloaddition of DA cyclobutanes51 was recently reported 
by France and co-workers.52,53 The authors described a Sc(OTf)3-catalyzed [5+2] 
cycloaddition approach for the synthesis of azepino[1,2-a]indoles 1-94 via DA 
cyclobutane intermediates 1-95 (Scheme 1-20). 
 
Scheme 1-20. The [5+2] cycloaddition approach for synthesis of azepino[1,2-a]indoles 1-
94 via DA cyclobutane intermediates 1-95. 
In summary, application of the long ignored DA cyclobutanes in cycloaddition 
chemistry have recently garnered significant attention. A number of reaction partners 
have been found to undergo efficient annulations with DA cyclobutanes to facilitate rapid 
access to structurally intriguing carbo- and heterocyclic frameworks. While initial 
examples lacked scope and stereochemical control, more recent examples have 
broadened the scope of the transformations, and have demonstrated the possibility of high 
level of stereo-control. Recently, asymmetric and intramolecular cycloaddition variants 
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have been reported, yet the chemistry of DA cyclobutanes is only in its infancy and 
further studies will surely prove fruitful. 
Motivated by the successful cycloadditions of AACDs with aldehydes, imines, 
and nitrones, we became interested in exploring the reactivity of other dipolarophiles, as 
this would allow a better understanding of these fascinating systems. A successful 
cycloaddition would result in diverse structural motifs, depending on the dipolarophile, 
and would thus be useful in accessing a library of compounds for biological screening. In 
addition, as many natural products contain these cycloadducts as core structures, it would 
be very efficient to elaborate these cycloadducts for complex natural product synthesis. 
Thus, we chose nitrosoarenes as annulation partners to investigate it’s reactivity with 
AACDs.  
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1.2 Results and Discussion 
1.2.1 Reactivity of Donor-Acceptor Cycloalkanes with Nitrosoarenes 
Nitrosoarenes54 have been utilized in a variety of transformations55 such as dienophiles in 
hetero Diels-Alder cycloadditions56 and as enophiles in nitroso-ene reactions.57  The 
dichotomous capacity of nitroso functional group, to act as either nitrogen or oxygen 
transfer reagents, has been well studied in nitroso-aldol chemistry.58 Although the 
insertion of NO into the cyclopropane ring is known,59 surprisingly, nitrosoarenes have 
not yet seen application in annelation60 chemistry with either DA cyclopropanes or 
cyclobutanes. 
1.2.1.1 The [4+2] Cycloaddition of AACDs with Nitrosoarenes 
In collaboration with fellow grad student Andrew C. Stevens (Ph.D. 2013) and 
undergrad Tyler B. Schon (B.Sc. 2011), investigations into the reactivity of AACDs with 
nitrosoarenes began with the examination of the reaction between cyclobutane 1-67b and 
nitrosobenzene (1-96a) (Table 1-5).61 While a variety of Lewis acids were found to 
catalyze the reaction, maximum yields were obtained with Yb(OTf)3. Additionally, the 
product yield was dramatically improved by decreasing the catalyst loading from 10 to 2 
mol % (compare entries 1, 6 and 8). The reaction could be effected with catalyst loadings 
as low as 0.5 mol % but in low yield (entry 9). Thus, 2 mol % Yb(OTf)3 was selected as 
the optimized catalysts system for this reaction. Interestingly, among the two possible 
regioisomers (1-97a and 1-98a), the product obtained was always 1-97a, and no 
noticeable amount of 1-98a was observed, irrespective of the Lewis acid used. Thereby 
28 
 
demonstrating that the nitrogen of the nitroso functional group was acting as a 
nucleophile rather than oxygen.62 
Table 1-5. Catalyst screening for [4+2] cycloaddition of AACDs with nitrosoarenes. 
 
entrya Lewis acid mol % yield (%)b product 
1 Yb(OTf)3 10 60 1-97a 
2 Sc(OTf)3 10 55 1-97a 
3 La(OTf)3 10 22 1-97a 
4 Zn(OTf)2 10 61 1-97a 
5 Pr(OTf)3 10 63 1-97a 
6 Yb(OTf)3 5 72 1-97a 
7 Sc(OTf)3 5 61 1-97a 
8 Yb(OTf)3 2 92 1-97a 
9 Yb(OTf)3 0.5 80 1-97a 
aTypical reaction conditions: To a solution of Lewis acid in CH2Cl2 (3 mL) 
at rt, was added nitrosobenzene 1-96a (0.30 mmol) followed by cyclobutane 
1-67b (0.36 mmol). Reactions were monitored until 1-96a was consumed by 
TLC. bIsolated yield. 
 
With optimal conditions in hand, the scope of the reaction was examined (Table 
1-6). It was discovered that nitrosoarenes with halogen substituents were excellent 
reaction partners regardless of the position on the aryl ring (entries 2-7).63  Substrates 
with moderately deactivating ketone (entries 8 and 9) or ester (entry 10) substituents were 
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competent in the reaction affording the product in good yields. Electron-deficient 
nitrosoarenes afforded moderate yields (entries 11 and 12); however, the other possible 
regioisomer (Figure 1-6) was also formed, comprising up to 25% of the isolated yield. 
Nitrosoarene with a weakly electron donating methyl substituent resulted in a 
substantially decreased yield (entry 13). Upon incorporation of a strongly electron 
donating group no reaction was observed (entries 14 and 15). The arrest in reactivity is 
likely due to the sequestration of the ytterbium catalyst by the electron-rich nitrosoarene. 
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Table 1-6. Reaction scope of the [4+2] cycloaddition of AACDs with nitrosoarenes. 
 
entry nitrosoarene product yield (%)b 
1 Ar = C6H5 1-97a 92 
2 Ar = 4-C6H4Br 1-97b 89 
3 Ar = 4-C6H4Cl 1-97c 93 
4 Ar = 3-C6H4Br 1-97d 87 
5 Ar = 3-C6H4Cl 1-97e 95 
6 Ar = 2,4-C6H3Br2 1-97f 47 
7 Ar = 3,4-C6H3Cl2 1-97g 91 
8 Ar = 4-C6H4C(O)Me 1-97h 69 
9 Ar = 3-C6H4C(O)Me 1-97i 87 
10 Ar = 4-C6H4CO2Et 1-97j 76 
11 Ar = 4-C6H4CN 1-97k, 1-98k (3:1)
a 61 
12 Ar = 4-C6H4NO2 1-97l, 1-98l (4:1)
a 59 
13 Ar = 4-C6H4Me 1-97m 29 
14 Ar = 4-C6H4OMe - no reaction
c 
15 Ar = 4- C6H4NMe2 - no reaction
c 
aRatio of 1-97:1-98 of isolated overall yield, bIsolated yield.  
cYb(OTf)3 2 mol % or 10 mol % 
 
Fortuitously, X-ray quality crystals of compounds 1-97b (entry 2, Table 1-6) and 
1-97k (entry 11, Table 1-6) were obtained and the ORTEP structures are depicted in 
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Figure 1-5. These crystal structures unambiguously establish both the regiochemistry of 
the cyclization and the relative stereochemistry at the ring fusion.64  
 
 
 
 
 
 
Figure 1-5. ORTEP structures of 1-97b and 1-97k. 
(Reproduced with permissions from ref. 61) 
 Extensive 2D NMR analysis was used to support the structural assignments of the 
isomers formed with electron deficient nitrosoarenes (entries 11 and 12, Table 1-6). The 
major isomer in each case was found to have nOe and 1H-15N HMBC interactions that 
were consistent with those observed for 1-97b and 1-97k (Figure 1-6). The minor isomer 
showed nOe interactions suggesting a cis ring fusion, and 1H-15N HMBC data indicated 
that it is a regioisomer, rather than a diastereomer, was formed. Similar nOe and 1H-15N 
HMBC correlations were observed for 1-97l and 1-98l also.  This lack of selectivity 
could be due to delocalization of the nitrogen lone pair of electrons into the aromatic ring, 
leading to competition between nitrogen and oxygen for dominant nucleophilicity. 
32 
 
 
Figure 1-6. Key nOe and 1H-15N HMBC correlations for structural assignment of 1-97k 
and 1-98k. 
As electron-rich nitrosoarenes were found not to participate in the Yb(OTf)3-
catalyzed cycloaddition, we reinvestigated the reaction conditions in attempts to find an 
alternative. Employing 1-methoxy-4-nitrosobenzene 1-96n as a model substrate, a 
thorough screening of catalysts was undertaken. In most cases, either no reaction or 
decomposition of the cyclobutane was observed (Table 1-7).65 However, a number of 
catalysts did afford the reaction product in small quantities. 
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Table 1-7. Catalyst screening for electron-rich nitrosoarenes. 
 
entrya catalyst mol % temp, time resultb 
1 Yb(OTf)3 50 rt, 30 min 19%
c 
2 Zn(OTf)2 10 rt, 20 h 13%
c 
3 ZnCl2 10 rt, 6 h 26%
c 
4 Zn(NTf2)2 10 rt, 2 h 1-98n-15% 
5 AlCl3 10 rt, 23 h 1-98n-9% 
6 AlBr3 10 rt, 72 h no reaction
f 
7 AlMe3 20 rt, 24 h no reaction
f 
8 MADNTf2 100 rt, 72 h no reaction
f 
9 Et2AlCl 20 0 °C, 2 h; rt, 18 h decomposition
e 
10 Sc(OTf)3 10 rt, 30 min decomposition
e 
11 CuI 10 rt, 52 h no reactionf 
12 Cu(OTf)2 10 rt, 30 min 1-98n-14%
  
13 SnCl2 10 rt, 46 h no reaction
f 
14 SnCl4 10 0 °C, 1 h decomposition
f 
15 Sn(OTf)2 10 rt, 18 h 1-98n-10%
  
16 Bu2BOTf 10 0 °C, 2 h; rt, 30 min decomposition
e 
17 BF3∙OEt2 10 0 °C, 4 h; rt, 18 h decompositione 
18 AgOTf 10 rt, 15 min decompositione 
19 AgCl 10 rt, 18 h decompositione 
20 ZrCl4 10 0 °C, 3 h; rt, 18 h decomposition
e 
21 TiCl4 10 0 °C, 3 h; rt, 18 h decomposition
e 
22 In(NTf2)3 10 rt, 30 min 1-98n-20% 
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23 In(OTf)3 10 rt, 3.5 h 1-98n-13% 
24 MgCl2 10 rt, 100 h no reaction
f 
25 MgBr2 10 rt, 120 h 1-98n-4% 
26 Mg(ClO4)2 10 0 °C, 4 h; rt, 2 h decomposition
e 
27 MgI2 10 rt, 23 h 1-98n-20% 
28 MgI2 5 rt, 24 h 1-98n-17% 
29 MgI2 10 0 °C, 40 h 1-98n-30% 
30 MgI2 10 -20 °C, 72 h 1-98n-20% 
31 MgI2 50 0 °C, 15 min 1-98n-26% 
aTypical reaction conditions: To a solution of Lewis acid in CH2Cl2 (3 mL) at 
specified temp, was added nitrosoarene 1-96n (0.30 mmol) followed by cyclobutane 
1-67b (0.36 mmol). Reactions were monitored until 1-96n was consumed by TLC. 
 bIsolated yields. c1:1 mixture 1-80n and another unknown compound by 1H NMR 
spectroscopy. dMicrowave irradiation. eCyclobutane 1-67b consumed.  
 fCyclobutane 1-67b recovered with some decomposition based on TLC  
and/or crude 1H NMR spectroscopy. 
 
Among all the Lewis acids tested, MgI2 was found to be functional for this 
reaction; however only low yields of product were obtained (entries 27-31, Table 1-7). 
Interestingly the regioisomer isolated under these conditions was the acetal 1-98n and not 
the aminal 1-97n as expected (compare with Table 1-6). This reversal in regioselectivity 
could be rationalized by the proposed mechanism (Scheme 1-21), in which the electron 
donating methoxy group on the aryl ring enhances the nucleophilicity of the nitroso 
oxygen, causing the oxygen to act as the nucleophile instead of nitrogen. Nucleophilic 
addition of the oxygen of the nitroso on the oxocarbenium ion 1-99 followed by 
cyclization via intermediate 1-100 would yield 1-98n. 
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Scheme 1-21. Proposed mechanism for the formation of 1-98n. 
During the course studying this reaction, a peculiar observation was noted. When 
the reaction was left to stir for 2 days at rt or when 1-98n was treated with 50 mol % 
MgI2 at rt overnight, pyrrolidine 1-101n was formed with trace amounts of lactone 1-
102n (Scheme 1-22). 
 
Scheme 1-22. Formation of pyrrolidine 1-101n and lactone 1-102n. 
The structural assignment for the deoxygenated pyrrolidine product 1-101n was 
made based on extensive 2D NMR analysis (Figure 1-7). The nOe correlations were 
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consistent with those observed for aminal regioisomer of oxazine 1-97 (See Figure 1-6) 
suggesting a cis ring fusion and an aminal linkage. The presence of 1H-15N HMBC 
correlations of nitrogen with all of the pyrrolidine protons, and a 1H-13C HMBC 
correlation between aminal proton and quaternary carbon supported the proposed 
structure which was in agreement with the observed mass in HRMS. 
 
Figure 1-7. Key nOe, 1H-15N HMBC, and 1H-13C HMBC correlations for structural 
assignment of 1-101n. 
A postulated mechanism to explain this redox transformation is depicted in 
Scheme 1-23.  
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Scheme 1-23. Proposed mechanism for the formation of 1-101n and 1-102n. 
Coordination of MgI2 to the oxygen of tetrahydro-1,2-oxazine 1-103 polarizes 
both the C-O and N-O bonds indicated. Cleavage of the C-O bond (Path A, Scheme 1-23) 
generates an oxocarbenium ion 1-104, which could then undergo nucleophilic attack by 
the pendant nitrogen, forming pyrrolidinium intermediate 1-105.  Finally, the initially 
displaced iodide reacts with the side chain on the nitrogen, resulting in N-O bond 
reduction, and concomitantly producing I2, MgO, and pyrrolidine 1-101n. Lactone 1-
102n can be formed via N-O bond cleavage of 1-103 (Path B) leading to intermediate 1-
106 followed by 1,5-hydride shift. 
Based on the proposed mechanism it is clear that stoichiometric MgI2 was 
necessary for complete conversion of 1-98n to 1-101n, but disappointingly the yields 
were further lowered with considerable decomposition of cyclobutane under such 
conditions.  
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With these interesting results we proceeded to investigate if other nitrosoarenes 
would follow a similar reaction manifold under MgI2-promoted conditions. Thus, the 
reaction of electron-rich nitrosoarene 1-96o directly afforded pyrrolidine 1-101o (entry 2, 
Table 1-8), without observation of the anticipated tetrahydro-1,2-oxazine 1-98o. 
Interestingly, the substrate 1-96k, which afforded aminal 1-97k as the major product 
under Yb(OTf)3 catalysis (entry 11, Table 1-6), resulted in reversal of regioselectivity 
albeit in low yield (entry 3, Table 1-8). Also, the isolated aminal 1-107k was found to be 
the trans-diastereomer (confirmed by single-crystal X-ray diffraction; see, Figure 1-8), 
rather than cis. Nitrosobenzene 1-96a, which is electronically sandwiched between 1-96n 
and 1-96k, produced aminal 1-97a as the exclusive product, ruling out the possibility of 
Mg-enolate aldol reaction mechanism.66 The nitroso-heteroarenes 2-nitrosopyridine (1-
96p) and N-Boc-5-nitrosoindole (1-96q), which did not react under Yb(OTf)3 conditions, 
provided exclusive acetal products (1-98 and 1-98q respectively) in low yields (entries 5 
and 6, Table 1-8). 
  
39 
 
Table 1-8. Scope of MgI2-promoted cycloaddition. 
 
entrya nitrosoarene product MgI2 (mol %) yield (%)c 
1 1-96n Ar = 4-C6H4OMe 1-101n 50 26
 
2 1-96o Ar = 4-C6H4NMe2 1-101o 50 22 
3 1-96k Ar = 4-C6H4CN 
1-98k, 1-107k 
(2:1)b 
10 
35 
4 1-96a Ar = C6H5 1-97a 10 56 
5 1-96p Ar = 2-pyridine 1-98p 50 28 
6 1-96q Ar = N-Boc-5-nitrosoindole 1-98q 10 19 
aTypical reaction conditions: To a solution of MgI2 in CH2Cl2 (3 mL) at specified temp, 
was added nitrosoarene 1-96 (0.30 mmol) followed by cyclobutane 1-67b (0.36 mmol). 
Reactions were monitored until nitrosoarene 1-96 was consumed by TLC.  
bRatio of isolated overall yields. cIsolated yields. 
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Figure 1-8. ORTEP structure of oxazine 1-107k. 
Additional AACDs were explored under both Yb(OTf)3 and MgI2 reaction 
conditions (Table 1-9). AACD 1-67a gave a moderate yield with nitrosobenzene (1-96a) 
under Yb(OTf)3 catalysis, while electron-rich nitrosoarenes 1-96n and 1-96o resulted in 
low yields of exclusive pyrrolidine products 1-110an and 1-110ao respectively (entries 2 
and 3). The AACD 1-67g smoothly reacted with nitrosobenzene (1-96a) and 1-chloro-4-
nitrosobenzene 1-96c to furnish tetrahydro-1,2-oxazines 1-108ga and 1-108gc 
respectively in good yields (entries 4 and 5). Disappointingly the AACD 1-67f gave a 
poor yield with nitrosobenzene (1-96a), while electron-rich nitrosoarene 1-96n resulted 
in a low yield of acetal product 1-109fn (entry 7). 
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Table 1-9. Reaction scope of additional AACDs in [4+2] cycloaddition. 
 
entry cyclobutane nitrosoarene 
isolated yield 
Yb(OTf)3 MgI2 
1 
 
1-96a Ar = C6H5 
1-96n Ar = 4-C6H4OMe 
1-96o Ar = 4-C6H4N(CH3)2 
1-108aa, 45% 
- 
- 
- 
1-110an, 35% 
1-110ao, 18% 
2 
3 
4 
 
1-96a Ar = C6H5 
1-96c Ar = 4-C6H4Cl 
1-108ga, 73% 
1-108gc, 70% 
- 
- 5 
6 
 
1-96a Ar = C6H5 
1-96n Ar = 4-C6H4OMe 
1-108fa, 21% 
- 
- 
1-109fn, 38% 7 
 
Crystals of 1-110an were obtained and the X-ray structure was able to 
unambiguously confirm the structure of the pyrrolidine product (Figure 1-9). 
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Figure 1-9. ORTEP structure of 1-110an. 
(Reproduced with permissions from ref. 65) 
Knowing that 1-98n could be converted into pyrrolidine 1-101n via MgI2 
mediated reaction (Scheme 1-22), 1-109fn was subjected 50 mol % of MgI2 in attempts 
to form pyrrolidine 1-110fn. However, ester 1-111fn was the only product formed, and 
pyrrolidine 1-110fn was not observed (Scheme 1-24). 
 
Scheme 1-24. Formation of ester 1-111fn. 
In summary, we have developed the first example of [4+2] cycloaddition between 
AACDs and nitrosoarenes. The regiochemistry and relative stereochemistry of aminal 
products have been assigned by 2D NMR spectroscopy correlations and ultimately 
confirmed by single crystal X-ray diffraction. The reaction proceeds well with electron-
neutral and deficient nitrosoarenes but, electron-rich nitrosoarenes required much strong 
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Lewis acid, MgI2. Furthermore, a procedure to convert tetrahydro-1,2-oxazines into 
pyrrolidines was discovered. The regiochemistry and stereochemistry of the unexpected 
pyrrolidine products was assigned based on 2D NMR correlations and ultimately 
confirmed by single-crystal X-ray diffraction. Future work includes gaining mechanistic 
insights into the formation of pyrrolidines which will surely bring about new and exciting 
opportunities for furthering the efficiency of the process.  
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1.2.1.2 Cascade Reaction of Donor-Acceptor Cyclopropanes: Mechanistic Studies on 
Cycloadditions with Nitrosoarenes and cis-Diazenes 
The interesting results observed in cycloadditions of nitrosoarenes with AACDs spurred 
the investigation of similar reactivity with alkoxy-activated cyclopropanes. 
Unfortunately, the initial investigation only resulted in either no reaction or 
decomposition of the cyclopropane 1-12 despite a variety of conditions employed 
(Scheme 1-25).67 
 
Scheme 1-25. Anticipated [3+2] cycloaddition of DA cyclopropane 1-112 with 
nitrosobenzene (1-96a). 
While investigating for the best cycloaddition conditions, the Studer group 
reported an elegant [3+2] cycloaddition of DA cyclopropanes with nitrosoarenes.68 The 
reaction proceeds with complete retention of configuration and perfect control of 
regioselectivity (an example shown in Scheme 1-26). 
 
Scheme 1-26. Studer's [3+2] cycloaddition of DA cyclopropanes with nitrosoarenes. 
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The observed stereospecificity and regioselectivity (which is opposite to what was 
observed with AACDs, see Section 1.2.1.1), was rationalized by Studer and co-workers 
through the mechanism proposed below (Scheme 1-27).  
Scheme 1-27. Studer's proposed mechanism for the [3+2] cycloaddition. 
As per the authors, the catalyst MgBr2 first coordinates to the DA cyclopropane 
(S)-1-115a, providing the MgBr2-activated cyclopropane 1-118a. The bromide anion then 
opens the cyclopropane ring at the benzylic position in an SN2 fashion, generating Mg-
enolate 1-119a. This enolate 1-119a then undergoes a nitroso-aldol reaction with the 
nitrosobenzene (1-96a) likely via the 6-membered transition state 1-120a, to generate 
magnesiated hydroxylamine 1-121. Intermediate 1-121 then cyclizes through an 
intramolecular SN2 substitution to close the catalytic cycle, providing the isoxazole (S)-1-
116a with net retention at the stereogenic center with respect to the starting cyclopropane 
(S)-1-115a.  
Motivated by this reaction and previously reported Yb(OTf)3-catalyzed 
cycloadditions of DA cyclopropanes,69 we set out to investigate alternative reactivity of 
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DA cyclopropanes with nitrosoarenes under Yb(OTf)3 catalysis, aiming to secure the 
opposite regioisomer 1-123a. To our surprise, the reaction resulted in the formation of 
tetrahydro-1,2-oxazine 1-124aa instead of the anticipated isoxazolidine (1-123a, Scheme 
1-28). 
 
Scheme 1-28. Yb(OTf)3-catalyzed reaction of nitrosobenzene (1-96a) with DA 
cyclopropane 1-122a. 
  Interestingly, the yield of the reaction was slightly below 50%, but rose to 87% 
when two equiv of cyclopropane were used. After additional experimentation, it appeared 
that the reaction was consuming two equiv of the cyclopropane. A plausible mechanism 
that accounts for the observed stoichiometry requirements shown in Scheme 1-29. 
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Scheme 1-29. Proposed mechanism for the formation of tetrahydro-1,2-oxazine 1-124aa. 
As described in Scheme 1-29, the nitrogen of the nitrosobenzene (1-96a) opens 
the Yb(OTf)3-activated DA cyclopropane 1-125 resulting in intermediate 1-126, which 
instead of undergoing ring closure to give the expected cycloadduct isoxazolidine 1-123a 
(Path A), expels dimethyl 2-methylenemalonate (1-127a) producing nitrone 1-128a  (Path 
B). This in situ generated nitrone 1-128a then undergoes a well-known [3+3] 
cycloaddition with another equiv of Yb(OTf)3-activated DA cyclopropane 1-125 to 
furnish tetrahydro-1,2-oxazine 1-124aa (see Section 1.1.2.1). Interestingly, no evidence 
of recombination of nitrone 1-128a and dimethyl 2-methylenemalonate (1-127a) to form 
isoxazolidine 1-128a was observed. This could be due to the rapid polymerization of 
dimethyl 2-methylenemalonate (1-127a) under Yb(OTf)3 conditions. 
In order to substantiate the proposed mechanism and gain insights into this unique 
reaction, a crossover experiment was designed with two similar cyclopropanes, 1-122a 
and 1-122b, with nitrosobenzene (1-96a, Scheme 1-30). 
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Scheme 1-30. Crossover experiment for the reaction of DA cyclopropanes, 1-122a and 1-
122b, with nitrosobenzene (1-96a). 
(Experiment was conducted by Tristan Chidley) 
As expected, crossover products 1-124ba and 1-124ab were observed, supporting 
the formation of nitrone intermediates 1-128a and 1-128b (Scheme 1-30).  These 
products were identical to standards independently synthesized from literature 
procedures.11c 
It is interesting to note that this remarkable transformation has a reasonable 
substrate scope and could be used as a general method for the synthesis of tetrahydro-1,2-
oxazines (Table 1-10).13  Nitrosoarenes with halogen substituents resulted in good yields 
regardless of the position on the aryl ring (entries 2-4). Nitrosoarenes with a moderately 
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electron-withdrawing ketone (entry 5) or ester (entries 6-7) substituent were also found to 
be good reaction partners. Disappointingly, nitrosoarenes with strong electron-
withdrawing (entry 8) or electron-donating (entry 9) substituent resulted in 
decomposition products.70  Finally, a thiophene-substituted cyclopropane 1-122c was also 
shown to be a suitable reaction partner (entry 10).  
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Table 1-10. Scope of the cascade reaction. 
 
entrya Ar1 Ar time (h) yield (%)b 
1 Ph 1-96a, C6H5 13 87 
2 Ph 1-96d, 3-C6H4Br 24 73 
3 Ph 1-96b, 4-C6H4Br 24 75 
4 Ph 1-96g, 3,4-C6H3Cl2 12 91 
5 Ph 1-96i, 3-C6H4C(O)Me 20 68 
6 Ph 1-96r, 3-C6H4CO2Et 24 80 
7 Ph 1-96j, 4-C6H4CO2Et 23 78 
8 Ph 1-96k, 4-C6H4CN - - 
9 Ph 1-96n, 4-C6H4OMe - - 
10 2-thienyl 1-96a, C6H5 7 69 
(Conducted in collaboration with Tristan Chidley) 
aReaction conditions: To a solution of cyclopropane 1-122 and nitrosoarene 1-96  
in (CH2)2Cl2 at rt, was added Yb(OTf)3·H2O, and then heated at reflux for specified time. 
bIsolated yields.
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With the mechanistic insight in hand, we began to reconsider the curious products 
isolated by the de Meijere group in GaCl3-catalyzed cycloadditions of diazene derivatives 
with DA cyclopropanes.71 We believe that the unusual product 1-132aa formed from cis-
diazene, 4-phenyl-1,2,4-triazoline-3,5-dione (1-130a, PTAD) and DA cyclopropane 1-
129a might have resulted through a similar mechanism via azomethine imine 
intermediate 1-133a (Scheme 1-31).  
 
Scheme 1-31. Proposed mechanism for de Meijere’s report on cycloaddition of cis-
diazene 1-130a with GaCl3-activated DA cyclopropane 1-129aa. 
As depicted in Scheme 1-31, one of the nitrogens of PTAD 1-130a opens the 
GaCl3-activated cyclopropane 1-129aa to form zwitterionic intermediate 1-131. This 
intermediate could then undergo either a cyclization to yield normal cycloadduct 1-132a 
(Path A) or fragment into azomethine imine 1-133a and diethyl 2 methylenemalonate (1-
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134a, Path B). Recombination of these latter two fragments would provide the 
cycloadduct 1-132aa. To validate this hypothesized mechanism, a crossover experiment 
was designed with two similar cyclopropanes, 1-129a and 1-129d, with PTAD 1-130a 
(Scheme 1-32).72 
 
Scheme 1-32. Crossover experiment for the reaction of DA cyclopropanes, 1-129a and 1-
129b, with cis-diazene 1-130a. 
(Experiment was conducted by Tristan Chidley) 
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As anticipated, the reaction did yield crossover products 1-132ad, 1-132dd, 1-
132aa, and 1-132da, thus providing strong evidence for the formation of azomethine 
imines 1-133a and 1-133d in the reaction. All of the crossover products were identical 
with standards independently synthesized from de Meijere’s method.71 The gas 
chromatogram in Figure 1-10 shows relative ratios of all six products in the crude 
mixture of a representative crossover experiment.73 
 
Figure 1-10. Gas chromatogram of the crude product of crossover experiment of 
cycloaddition of DA cyclopropanes, 1-129a and 1-129d, with cis-diazene 1-130a. 
In summary, we discovered a cascade process in reactions of DA cyclopropanes 
with nitrosoarenes. The reaction results in tetrahydro-1,2-oxazines via nitrone 
intermediates in good to excellent yields as single diastereomers. Mechanistic insights 
gained by crossover experiments on this unique transformation enabled a better rationale 
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for peculiar products formed in GaCl3-catalyzed cycloaddition of PTAD with DA 
cyclopropanes. As the chemistry of DA cyclopropanes is constantly expanding, we 
believe this mechanistic observation serves as a caution for the cascade processes. 
Additionally, this study reveals new opportunities for reaction design in DA 
cyclopropane chemistry.  
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1.2.2 The [4+2] Cycloaddition of AACDs with cis-Diazenes 
Diazenes are well-known in the literature largely for use as dienophiles for hetero Diels-
Alder chemistry.74  Also, diazenes are competent dipolarophiles in GaCl3-catalyzed [3+2] 
cycloadditions with DA cyclopropanes furnishing pyrazolidine derivatives 1-135 (eq 1, 
Scheme 1-33).71  Given this precedent, and our ongoing interest in DA cyclobutane 
chemistry (see Section 1.1.3.3), we sought to access hexahydropyridazines 1-136 through 
Lewis acid-catalyzed [4 + 2] cycloaddition of AACDs and diazenes (eq 2, Scheme 1-33). 
The resulting hexahydropyridazine derivatives75 are of interest for their prevalence in 
biologically relevant and structurally interesting molecules (Figure 1-11).76 
 
Scheme 1-33. Cycloaddition of diazenes with DA cyclopropanes and DA cyclobutanes. 
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Figure 1-11. Representative examples of hexahydropyridazine core in synthetic 
pharmaceuticals and natural products. 
In collaboration with fellow graduate student Tristan Chidley, we began our 
studies by examining the reactivity of AACD 1-67b with commercially available trans-
diazenes diethyl azodicarboxylate (DEAD) and azobenzene, with either Yb(OTf)3  or 
GaCl3  catalysis with a variety of conditions, but unfortunately these attempts only 
resulted in slow decomposition of AACD 1-67b. Fortunately, the cis-diazene PTAD (1-
130a)77  was found to engage in cycloaddition to yield hexahydropyridazine 1-136b as a 
single diastereomer albeit in poor yield (Scheme 1-34).  
 
Scheme 1-34. Cycloaddition of cis-diazene 1-130a with AACD 1-67b. 
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Quick optimization established 5 mol % GaCl3 as optimal to catalyze the reaction 
(Table 1-11). With the optimal conditions in hand, we then investigated the scope of the 
reaction using PTAD 1-130a and a variety of AACDs (Table 1-11).  
Table 1-11. The [4+2] cycloaddition of cis-diazene 1-130a with AACDs. 
 
 
 
Reaction conditions: To a solution of cyclobutane 1-67 (0.40 mmol, 2.0 
equiv) and PTAD 1-130a (0.20 mmol, 1.0 equiv) in DCE (2 mL) at rt 
was added a solution of GaCl3 (0.01 mmol, 0.05 equiv) in DCE (1 mL) 
and stirred until 1-130a was fully consumed (by TLC). 
The pyran-fused cyclobutane 1-67a resulted in a 78% isolated yield while the 
ethoxy substituted cyclobutane 1-67f afforded hexahydropyridazine in 90% yield. 
Densely functionalized cyclobutanes 1-67g and 1-67l also caused excellent conversions 
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to hexahydropyridazines 1-136g and 1-136l respectively. Finally, an aryl substituted 
cyclobutane 1-67h was also found to engage in the cycloaddition. 
Due to thermal instability and short shelf-life of the other reported cis-diazenes, 
we were unable to expand the scope of the reaction to additional cis-diazenes. 
Fortuitously, X-ray quality crystals of cycloadduct 1-136a (Table 1-11) were 
obtained and the ORTEP structure depicted in Figure 1-12.78  The crystal structure shows 
the relative cis stereochemistry at the ring fusion. 
 
 
 
Figure 1-12. ORTEP structure of hexahydropyridazine 1-136a. 
In summary, we have developed the first example of a [4+2] cycloaddition 
between AACDs and cis-diazene. The relative cis stereochemistry at ring fusion has been 
assigned based on nOe correlations and confirmed by single crystal X-ray diffraction. 
The reaction proceeds smoothly with alkoxy activated cyclobutanes as well as aryl 
activated cyclobutanes to form hexahydropyridazines in good to excellent yields.  
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1.2.3 Spiroketals from AACDs 
Spiroketals are abundant substructures of natural products from many sources, including 
but not limited to, insects, microbes, plants, fungi, and marine organisms (Figure 1-13).79 
Interesting pharmacological properties of these compounds   resulted in significant 
research in both their synthesis and chemical reactivity.80 
 
Figure 1-13. Representative examples of spiroketal-containing natural products. 
Two of the most common strategies towards the synthesis of spiroketals is acid-
catalyzed dehydration of dihydroxy ketones (eq 1, Scheme 1-35)79e and transition metal-
mediated cyclizations of internal alkynes (eq 2, Scheme 1-35).81 Although these methods 
efficiently construct spiroketals, additional methods would be desirable for regio- and 
stereoselective synthesis of spiroketals.  
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Scheme 1-35. Two common strategies towards the synthesis of spiroketal. 
 Recently, our group reported a cycloaddition between AACDs and a wide range 
of aldehydes under Yb(OTf)3 catalysis to generate fused acetals with exclusive cis-
stereochemistry (see Section 1.1.3.3.1). Now we anticipated that the same chemistry 
could be applied to spirocyclic AACDs to efficiently access spiroketals (Scheme 1-36).  
 
Scheme 1-36. Proposed synthesis of spiroketals from spirocyclic AACDs. 
 We set out to synthesize the spirocyclic AACDs under previously successful 
conditions with AACDs (see Section 1.1.3.2). The required enol ethers were prepared 
from β-elimination of corresponding chloroethyl ethers using literature procedures.82  
Initial investigation established 5 mol % of Zn(OTf)2 at -78 °C in dichloromethane as the 
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best conditions for this reaction (Scheme 1-37). Nevertheless, both preventing the 
formation of the decomposition product 1-149a in the reaction or purification of the 
product 1-143a turned out to be insurmountable and ultimately partially purified product 
1-143a was carried forwarded to the next step.83  
 
Scheme 1-37. Synthesis of spirocyclic AACD 1-143a. 
 In order to examine the proposed synthesis of spiroketals, we tested the reactivity 
of partially purified 1-143a with benzaldehyde (1-150a) under Yb(OTf)3 conditions. 
Satisfyingly the reaction did produce the spiroketal as a single diastereomer in moderate 
45% yield (Scheme 1-38).  
 
Scheme 1-38. Synthesis of spiroketal 1-145a via a [4+2] cycloaddition of AACD 1-143a 
and benzaldehyde (1-150a). 
In summary, we accomplished the spiroketal 1-145a synthesis from spirocyclic 
AACD 1-143a. Although the yield is moderate, this result serves as a proof of concept. 
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Efforts are now underway to isolate the AACD 1-143a in pure form to further optimize 
the reaction conditions and to examine the reaction scope. 
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1.3 Conclusions and Outlook 
In summary, we have developed the first example of a [4+2] cycloaddition between DA 
cyclobutanes and nitrosoarenes. The regiochemistry and relative stereochemistry of the 
cycloadducts have been assigned based on 1H-15N HMBC spectroscopy and confirmed by 
single crystal X-ray diffraction. The reaction proceeds well with electron neutral and 
deficient nitrosoarenes to form tetrahydro-1,2-oxazines. We have also discovered the 
formation of unexpected pyrrolidine products in the MgI2 promoted [4+2] cycloaddition 
between DA cyclobutanes and electron-rich nitrosoarenes. Furthermore, a procedure to 
make pyrrolidines from tetrahydro-1,2-oxazines was reported. The regiochemistry and 
stereochemistry of the unexpected pyrrolidine product has been unambiguously assigned 
by single-crystal X-ray diffraction. Future work includes mechanistic insights into the 
unexpected formation of pyrrolidines, and to further increase the efficiency of this 
transformation. In short, the reaction of DA cyclobutanes and nitrosoarenes could be used 
as a general method to access either tetrahydro-1,2-oxazine or pyrrolidine products, 
depending on the electronics of the nitrosoarenes.  
A cascade process was discovered in Yb(OTf)3-catalyzed reactions of 
nitrosoarenes with DA cyclopropanes. The reaction underwent a tandem ring-opening, 
elimination, and cyclization sequence to form tetrahydro-1,2-oxazines via nitrone 
intermediates in good to excellent yields as single diastereomers. Mechanistic insights 
gained by crossover experiments on this unique transformation enabled a better rationale 
for peculiar products formed in GaCl3-catalyzed cycloaddition of cis-diazene PTAD with 
DA cyclopropanes. Overall, this study serves as a warning for the cascade processes in 
DA cyclopropane chemistry and reveals new opportunities for reaction design. 
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We have also developed the first example of a [4+2] cycloaddition between 
AACDs and cis-diazenes. The relative cis stereochemistry of the cycloadducts has been 
assigned based on single crystal X-ray diffraction. The reaction proceeds efficiently with 
all the AACDs investigated to form hexahydropyridazines in good to excellent yields, 
suggesting the potential use as a general method. Expansion of the substrate scope to 
additional cis-diazenes and application towards the synthesis of synthetic pharmaceutical 
Pralnacasan are currently under investigation. 
Finally, we demonstrated the application of spirocyclic AACD in spiroketal 
synthesis. Although, we only disclosed one example, this serves as a proof of concept to 
motivate further studies.  
To conclude, exploitation of ring strain in carbocycles to generate dipolar 
intermediates for cycloaddition chemistry, has become an efficient strategy in modern 
organic synthesis. Despite the plethora of discoveries already made in DA cyclopropane 
chemistry, there are still opportunities for new chemistries to uncover (such as the 
cascade reaction we discovered). On the other hand, the long ignored DA cyclobutanes 
has only recently garnered attention. Regardless of the reactions disclosed, elaboration of 
these cycloaddition adducts remains to be exploited for the synthesis of complex natural 
products. Overall, the chemistry of DA cyclobutanes is only in its infancy and further 
investigation will surely benefit the synthetic community.  
65 
 
1.4 Experimental 
1.4.1 General Considerations 
All reactions were run under argon atmosphere unless otherwise indicated. Flasks were 
oven dried at approximately 120 °C and cooled in a dessicator prior to use. Solvents and 
reagents were purified by standard methods.84 Yb(OTf)3 used as mono hydrate as 
obtained from Sigma-Aldrich®.  All other chemicals were of reagent quality and used as 
obtained from commercial sources unless otherwise noted. The progress of reactions 
were monitored by thin layer chromatography (TLC) performed on F254 silica gel plates. 
The plates were visualized by UV light (254 nm) or by staining with ceric ammonium 
molybdate (CAM). Column chromatography was performed with Silica Flash P60 60 Å 
silica gel from SiliCycle® according to the Still method.85 
The 1H and 13C NMR data were obtained on either 400 or 600 MHz 
spectrometers. All spectra were obtained in deuterated chloroform and were referenced to 
the residual chloroform at 7.26 ppm for 1H spectra and the center signal of the triplet at 
77.0 ppm for 13C spectra. Scalar coupling was eliminated from nOe experiments by using 
acquisition delays of 500 ms. Electron ionization mass spectra were obtained on a 
Finnigan MAT 8400 spectrometer at an ionizing voltage of 70 eV. GC/MS analyses of 
the samples were performed on a Shimadzu GCMS-QP2010 Chromatography-Ion trap 
mass spectrometer. A DB-5MS (J&W Scientific) (30 m X 0.25 mm i.d. and 0.25 (m film 
thickness) capillary column was used; carrier gas helium (1 mL/min). Temperature 
program for the oven: 200 °C (3 min), 320 °C at 6 °C/min. Ion source temp 250 °C; 
interface temp 250 °C; solvent cut time 0.5 min; time 2-28 min; scan, m/z 45-600. The 
microwave reaction was conducted in an Initiator reactor from Biotage®.  
66 
 
1.4.2 Cycloadditions of AACDs and Nitrosoarenes 
Nitrosoarenes, which are not commercially available, were prepared from the 
corresponding anilines according to literature methods.86 AACDs were prepared 
according to the literature procedure, except 5 mol % of Zn(OTf)2 was used instead of 10 
mol % Yb(OTf)3.
87 
General Cycloaddition Procedure A 
To a mixture of nitrosoarene (0.30 mmol, 1.0 equiv) and Yb(OTf)3·H2O (4 mg, 0.006 
mmol, 2 mol %) in CH2Cl2 (3 mL) at rt was added cyclobutane (0.36 mmol, 1.2 equiv). 
After complete consumption of the nitrosoarene (as indicated by TLC) the reaction 
mixture (RM) was layered directly onto a silica gel column and purified by flash 
chromatography (0-25% EtOAc/hexanes). 
General Cycloaddition Procedure B 
To a stirred solution of MgI2 (41.5 mg, 0.15 mmol, 50 mol %) in CH2Cl2 (3 mL) at 0 °C 
was added nitrosoarene (0.30 mmol, 1.0 equiv) followed by cyclobutane (0.36 mmol, 1.2 
equiv). After complete consumption of the nitrosoarene (as indicated by TLC) the RM 
was layered directly onto a silica gel column and purified by flash chromatography (0-
25% EtOAc/hexanes). 
Compounds 1-97b, 1-97f, 1-97h, and 1-97m were prepared either by Andrew C. Stevens 
(Ph.D. 2013) or Tyler B. Schon (B.Sc. 2011) and are not shown below. 
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Characterization Data  
 
Compound 1-97a 
The title compound was prepared according to the general cycloaddition procedure A to 
afford pale yellow oil (96 mg, 92%).  
Rf = 0.27 (30% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.26 - 7.35 (m, 4 H), 6.97 - 7.02 (m, 1 H), 5.44 (d, J = 5.9 
Hz, 1 H), 4.25 - 4.33 (m, 2 H), 4.15 - 4.24 (m, 2 H), 4.09 (td, J = 6.8, 8.5 Hz, 1 H), 3.93 
(td, J = 3.9, 8.2 Hz, 1 H), 2.80 - 2.90 (m, 1 H), 2.60 (dd, J = 6.6, 14.1 Hz, 1 H), 2.16 (dq, 
J = 8.2, 12.7 Hz, 1 H), 2.04 (dd, J = 8.6, 14.1 Hz, 1 H), 1.83 - 1.92 (m, 1 H), 1.29 (t, J = 
7.2 Hz, 3 H), 1.18 (t, J = 7.2 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 167.9, 167.6, 146.7, 128.5, 123.0, 117.5, 88.6, 83.6, 67.0, 
62.2, 62.0, 33.3, 30.6, 29.6, 14.0, 13.9. 
HRMS (m/z): 349.1525 (calcd for C18H23NO6, 349.1525). 
 
Compound 1-97c 
The title compound was prepared according to the general cycloaddition procedure A to 
afford colorless oil (109 mg, 93%).  
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Rf = 0.30 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 7.21 - 7.29 (m, 4 H), 5.37 (d, J = 5.9 Hz, 1 H), 4.14 - 4.33 
(m, 4 H), 4.05 - 4.10 (m, 1 H), 3.92 (td, J = 8.3, 3.8 Hz, 1 H), 2.80 - 2.88 (m, 1 H), 2.58 
(dd, J = 14.1, 6.4 Hz, 1 H), 2.15 (dq, J = 12.4, 8.2 Hz, 1 H), 2.07 (dd, J = 14.1, 8.2 Hz, 1 
H), 1.85 - 1.92 (m, 1 H), 1.28 (t, J = 7.3 Hz, 3 H), 1.18 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 167.7, 167.5, 145.4, 128.5, 128.1, 118.9, 88.7, 83.6, 67.1, 
62.2, 62.1, 33.4, 30.5, 29.4, 14.0, 14.0. 
HRMS (m/z): 383.1128 (calcd for C18H22ClNO6, 383.1136). 
 
Compound 1-97d 
The title compound was prepared according to the general cycloaddition procedure A to 
afford a colorless thick mass (112 mg, 87%).  
Rf = 0.32 (30% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.52 - 7.55 (m, 1 H), 7.17 - 7.23 (m, 1 H), 7.10 - 7.14 (m, 
2 H), 5.40 (d, J = 5.9 Hz, 1 H), 4.25 - 4.36 (m, 2 H), 4.16 - 4.25 (m, 2 H), 4.09 (td, J = 
8.3, 6.8 Hz, 1 H), 3.93 (td, J = 8.2, 3.9 Hz, 1 H), 2.78 - 2.90 (m, 1 H), 2.60 (dd, J = 14.3, 
6.5 Hz, 1 H), 2.04 - 2.21 (m, 2 H), 1.84 - 1.93 (m, 1 H), 1.30 (t, J = 7.0 Hz, 3 H), 1.21 (t, 
J = 7.2 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 167.7, 167.4, 147.9, 129.8, 125.7, 122.5, 120.5, 115.5, 
88.5, 83.6, 67.2, 62.3, 62.2, 33.3, 30.5, 29.3, 14.0, 13.9. 
HRMS (m/z): 427.0621 (calcd for C18H22BrNO6, 427.0631). 
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Compound 1-97e 
The title compound was prepared according to the general cycloaddition procedure A to 
afford pale yellow color oil (111 mg, 95%).  
Rf = 0.30 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 7.38 - 7.41 (m, 1 H), 7.14 - 7.22 (m, 2 H), 6.97 (dd, J = 
7.6, 1.8 Hz, 1 H), 5.42 (d, J = 5.9 Hz, 1 H), 4.26 - 4.36 (m, 2 H), 4.16 - 4.26 (m, 2 H), 
4.07 - 4.13 (m, 1 H), 3.94 (td, J = 8.2, 4.1 Hz, 1 H), 2.82 - 2.89 (m, 1 H), 2.61 (dd, J = 
14.1, 6.4 Hz, 1 H), 2.16 (dq, J = 12.6, 8.1 Hz, 1 H), 2.10 (dd, J = 14.1, 7.6 Hz, 1 H), 1.87 
- 1.94 (m, 1 H), 1.31 (t, J = 7.0 Hz, 3 H), 1.21 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 167.7, 167.5, 147.9, 134.4, 129.5, 122.8, 117.8, 115.1, 
88.6, 83.7, 67.2, 62.3, 62.2, 33.4, 30.5, 29.3, 14.0, 13.9. 
HRMS (m/z): 383.1132 (calcd for C18H22ClNO6, 383.1136). 
 
Compound 1-97g 
The title compound was prepared according to the general cycloaddition procedure A to 
afford a pale yellow color paste (114 mg, 91%).  
Rf = 0.25 (30% EtOAc/hexanes). 
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1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 2.3 Hz, 1 H), 7.32 (d, J = 8.8 Hz, 1 H), 7.15 
(dd, J = 8.8, 2.3 Hz, 1 H), 5.37 (d, J = 6.4 Hz, 1 H), 4.26 - 4.35 (m, 2 H), 4.17 - 4.26 (m, 
2 H), 4.06 - 4.11 (m, 1 H), 3.94 (td, J = 8.3, 4.4 Hz, 1 H), 2.81 - 2.89 (m, 1 H), 2.59 (dd, J 
= 14.1, 6.4 Hz, 1 H), 2.09 - 2.20 (m, 2 H), 1.87 - 1.94 (m, 1 H), 1.31 (t, J = 7.3 Hz, 3 H), 
1.22 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 167.6, 167.3, 146.3, 132.4, 130.0, 126.0, 119.5, 116.6, 
88.7, 83.7, 67.3, 62.4, 62.2, 33.5, 30.4, 29.2, 14.0, 14.0. 
HRMS (m/z): 417.0737 (calcd for C18H21Cl2NO6, 417.0746). 
 
Compound 1-97i 
The title compound was prepared according to the general cycloaddition procedure A to 
afford pale yellow colored oil (103 mg, 87%).  
Rf = 0.39 (30% EtOAc/hexanes, double elution). 
1H NMR (400 MHz, CDCl3) δ 7.87 - 7.91 (m, 1 H), 7.55 - 7.62 (m, 2 H), 7.34 - 7.41 (m, 
1 H), 5.49 (d, J = 5.9 Hz, 1 H), 4.25 - 4.35 (m, 2 H), 4.20 (q, J = 7.0 Hz, 2 H), 4.05 - 4.13 
(m, 1 H), 3.94 (td, J = 8.4, 3.9 Hz, 1 H), 2.81 - 2.92 (m, 1 H), 2.59 - 2.65 (m, 1 H), 2.58 
(s, 3 H), 2.02 - 2.23 (m, 2 H), 1.84 - 1.95 (m, 1 H), 1.30 (t, J = 7.0 Hz, 3 H), 1.18 (t, J = 
5.9 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 198.0, 167.7, 167.4, 147.1, 137.5, 128.8, 122.9, 122.1, 
117.0, 88.6, 83.7, 67.1, 62.3, 62.1, 33.3, 30.5, 29.4, 26.7, 14.0, 13.9. 
HRMS (m/z):  391.1636 (calcd for C20H25NO7, 391.1631). 
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Compound 1-97j 
The title compound was prepared according to the general cycloaddition procedure A to 
afford pale yellow oil (104 mg, 76%).  
Rf = 0.21 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 7.95 - 7.98 (m, 2 H), 7.31 - 7.34 (m, 2 H), 5.55 (d, J = 5.9 
Hz, 1 H), 4.27 - 4.36 (m, 4 H), 4.15 - 4.24 (m, 2 H), 4.08 - 4.13 (m, 1 H), 3.94 (td, J = 
8.2, 4.1 Hz, 1 H), 2.84 - 2.91 (m, 1 H), 2.63 (dd, J = 14.1, 6.5 Hz, 1 H), 2.17 (dq, J = 
12.6, 8.1 Hz, 1H), 2.11 (dd, 14.4, 7.9 Hz, 1H), 1.88 - 1.94 (m, 1 H), 1.37 (t, J = 7.3 Hz, 3 
H), 1.31 (t, J = 7.0 Hz, 3 H), 1.15 - 1.18 (m, 3 H). 
13C NMR (101 MHz, CDCl3) δ 167.6, 167.2, 166.4, 150.4, 130.3, 124.2, 115.8, 88.0, 
83.6, 67.2, 62.3, 62.1, 60.5, 33.1, 30.5, 29.2, 14.3, 13.9, 13.9. 
HRMS (m/z): 421.1742 (calcd for C18H23NO6, 421.1737). 
 
Compound 1-97k 
The title compound was prepared according to the general cycloaddition procedure A to 
afford a cream colored solid (67 mg, 46%).  
Rf = 0.22 (30% EtOAc/hexanes). 
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1H NMR (600 MHz, CDCl3) δ 7.55 - 7.58 (m, 2 H), 7.37 - 7.40 (m, 2 H), 5.52 (d, J = 5.9 
Hz, 1 H), 4.27 - 4.36 (m, 2 H), 4.16 - 4.25 (m, 2 H), 4.07 - 4.12 (m, 1 H), 3.94 (td, J = 
8.2, 4.1 Hz, 1 H), 2.85 - 2.92 (m, 1 H), 2.61 (dd, J = 14.7, 6.5 Hz, 1 H), 2.14 - 2.22 (m, 2 
H), 1.90 - 1.96 (m, 1 H), 1.31 (t, J = 7.0 Hz, 3 H), 1.18 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 167.4, 167.0, 150.2, 132.8, 119.3, 116.6, 105.1, 87.9, 
83.7, 67.4, 62.5, 62.3, 33.3, 30.4, 29.0, 14.0, 13.9. 
HRMS (m/z): 374.1482 (calcd for C19H22N2O6, 374.1478).  
 
Compound 1-98k 
The title compound was isolated as a byproduct along with 1-97k as yellow oil (22 mg, 
15%).  
Rf = 0.22 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 7.46 - 7.50 (m, 2 H), 7.09 - 7.13 (m, 2 H), 5.57 (d, J = 5.3 
Hz, 1 H), 4.28 (q, J = 7.0, 2 H), 4.10 - 4.21 (m, 3 H), 4.02 (td, J = 8.2, 3.5 Hz, 1 H), 2.65 
- 2.70 (m, 1 H), 2.60 - 2.65 (m, 1 H), 2.54 - 2.59 (m, 1 H), 2.08 - 2.18 (m, 1 H), 1.87 - 
1.94 (m, 1 H), 1.25 (t, J = 7.0 Hz, 3 H), 1.13 (t, J = 7.3 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 168.2, 168.2, 150.6, 132.4, 119.5, 116.0, 104.9, 104.0, 
72.9, 68.7, 62.7, 62.4, 35.4, 33.0, 29.6, 13.9, 13.8. 
HRMS (m/z): 374.1489 (calcd for C19H22N2O6, 374.1478). 
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Compound 1-97l 
The title compound was prepared according to the general cycloaddition procedure A to 
afford a yellow solid (56 mg, 47%).  
Rf = 0.19 (30% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 8.14 - 8.20 (m, 2 H), 7.38 - 7.42 (m, 2 H), 5.58 (d, J = 6.3 
Hz, 1 H), 4.28 - 4.36 (m, 2 H), 4.17 - 4.24 (m, 2 H), 4.11 (q, J = 7.9 Hz, 1 H), 3.95 (td, J 
= 8.2, 4.3 Hz, 1 H), 2.86 - 2.94 (m, 1 H), 2.63 (dd, J = 14.1, 6.3 Hz, 1 H), 2.15 - 2.24 (m, 
2 H), 1.91 - 1.98 (m, 1 H), 1.32 (t, J = 7.2 Hz, 3 H), 1.18 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 167.3, 167.0, 152.0, 142.3, 124.7, 115.8, 88.0, 83.7, 67.5, 
62.6, 62.4, 33.4, 30.3, 28.9, 14.0, 13.9. 
HRMS (m/z): 394.1377 (calcd for C18H22N2O8, 394.1376). 
 
Compound 1-98l 
The title compound was isolated as a byproduct along with 1-97l as yellow colored oil 
(14 mg, 12%).  
Rf = 0.19 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 8.08 - 8.11 (m, 2 H), 7.05 - 7.09 (m, 2 H), 5.59 (d, J = 5.3 
Hz, 1 H), 4.26 - 4.34 (m, 2 H), 4.17 - 4.23 (m, 2 H), 4.10 - 4.15 (m, 1 H), 4.04 (td, J = 
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8.2, 3.5 Hz, 1 H), 2.63 - 2.69 (m, 2 H), 2.54 - 2.58 (m, 1H), 2.10 - 2.18 (m, 1 H), 1.88 - 
1.92 (m, 1 H), 1.27 (t, J = 7.0 Hz, 3 H), 1.15 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 167.8, 167.8, 152.0, 140.9, 124.3, 114.2, 105.0, 72.4, 
68.5, 62.8, 62.5, 35.3, 32.9, 29.7, 13.8, 13.7. 
HRMS (m/z): 394.1377 (calcd for C18H22N2O8, 394.1376). 
 
Compound 1-98n 
The title compound was prepared according to the general cycloaddition procedure B to 
afford a pale yellow paste (30 mg, 26%). 
Rf = 0.41 (50% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 7.24 – 7.26 (m, 2 H), 6.75 – 6.77 (m, 2 H), 5.55 (d, J = 
5.3 Hz, 1 H), 4.20 – 4.24 (m, 1 H), 4.15 – 4.19 (m, 1 H), 4.07 – 4.13 (m, 2 H), 4.01 – 4.06 
(m, 1 H), 3.96 (td, J = 8.1, 5.0 Hz, 1 H), 3.76 (s, 3 H), 2.61 – 2.72 (m, 2 H), 2.50 – 2.57 
(m, 1 H), 2.01 – 2.09 (m, 1 H), 1.95 (dq, J = 12.2, 6.3 Hz, 1 H), 1.14 (t, J = 7.0 Hz, 3 H), 
1.10 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 168.8, 156.6, 140.7, 122.7, 113.0, 104.5, 74.3, 
68.8, 61.9, 61.6, 55.4, 35.1, 32.3, 28.9, 13.8, 13.8. 
HRMS (m/z): 379.1635 (calcd for C19H25NO7, 379.1631). 
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Compound 1-101n 
To a stirred solution of MgI2 (44 mg, 0.16 mmol, 0.5 equiv) in 10 mL CH2Cl2 at rt was 
added 1-98n (120 mg, 0.32 mmol). The RM was stirred for about 18 h at rt (complete 
consumption of starting material by TLC) then the RM was layered directly onto a silica 
gel column and purified by flash chromatography (0-25% EtOAc/hexanes) to a brown oil 
(57 mg, 50%). 
Rf = 0.37 (50% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 6.90 – 6.94 (m, 2 H), 6.75 – 6.78 (m, 2 H), 5.62 (d, J = 
5.9 Hz, 1 H), 4.15 – 4.25 (m, 4 H), 3.91 – 4.00 (m, 2 H), 3.74 (s, 3 H), 3.00 – 3.07 (m, 1 
H), 2.70 (dd, J = 12.9, 8.8 Hz, 1 H), 2.39 (dd, J = 13.5, 8.8 Hz, 1 H), 2.00 – 2.08 (m, 1 
H), 1.72 (dd, J = 12.6, 5.0 Hz, 1 H), 1.21 (t, J = 7.3 Hz, 3 H), 1.18 (t, J = 7.3 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 170.7, 169.9, 153.4, 138.3, 117.6, 113.9, 98.6, 74.8, 65.5, 
61.8, 61.8, 55.5, 40.6, 40.1, 32.0, 14.0, 14.0. 
HRMS (m/z): 363.1692 (calcd for C19H25NO6, 363.1682). 
 
Compound 1-102n 
The title compound was isolated in trace amount along with 1-101n as a pale brown oil. 
Rf = 0.24 (70% hexanes /EtOAc). 
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1H NMR (600 MHz, CDCl3) δ 6.75 – 6.72 (m, 2 H), 6.65 – 6.62 (m, 2 H), 4.89 (s, 1 H), 
4.29 – 4.15 (m, 5 H), 4.06 (ddd, J = 11.2, 9.1, 6.2 Hz, 1 H), 3.72 (s, 3 H), 3.09 (dd, J = 
15.3, 3.5 Hz, 1 H), 2.67 – 2.60 (m, 1 H), 2.44 (dd, J = 15.3, 10.0 Hz, 1 H), 2.34 – 2.27 
(m, 1 H), 1.78 (qd, J = 11.7, 8.8 Hz, 1 H), 1.21 – 1.16 (m, 6 H). 
13C NMR (101 MHz, CDCl3) δ 178.8, 169.9, 169.2, 153.3, 137.5, 116.9, 114.7, 67.9, 
66.4, 62.5, 62.5, 55.5, 35.2, 33.7, 29.7, 13.9. 
HRMS (m/z): 379.1639 (calcd for C19H25NO7, 379.1631). 
 
Compound 1-101o 
The title compound was prepared according to the general cycloaddition procedure B at rt 
for 4 h to afford a yellow colored oil (25 mg, 22%). 
Rf = 0.33 (40% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 6.90 – 6.94 (m, 2 H), 6.66 – 6.70 (m, 2 H), 5.62 (d, J = 
5.9 Hz, 1 H), 4.13 – 4.24 (m, 4 H), 3.91 – 3.98 (m, 2 H), 2.99 – 3.06 (m, 1 H), 2.82 (s, 6 
H), 2.68 (dd, J = 13.5, 8.8 Hz, 1 H), 2.37 (dd, J = 13.2, 8.5 Hz, 1 H), 1.98 – 2.06 (m, 1 
H), 1.70 (dd, J = 12.6, 4.4 Hz, 1 H), 1.15 – 1.21 (m, 6 H). 
13C NMR (101 MHz, CDCl3) δ 170.9, 170.0, 145.3, 136.0, 118.2, 114.3, 98.7, 74.8, 65.4, 
61.7, 61.6, 41.7, 40.5, 40.0, 32.2, 14.0, 14.0. 
HRMS (m/z): 376.2044 (calcd for C20H28N2O5, 376.1998). 
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Compound 1-107k 
The title compound was prepared along with 1-98k according to the general 
cycloaddition procedure B, employing MgI2 (10 mol %) at rt for 2 h to afford a pale 
brown solid (15 mg, 13%). 
Rf = 0.44 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 7.60 – 7.63 (m, 2 H), 7.54 – 7.59 (m, 2 H), 4.22 – 4.34 
(m, 5 H), 4.06 – 4.15 (m, 2 H), 2.98 (dd, J = 12.9, 3.5 Hz, 1 H), 2.24 – 2.32 (m, 1 H), 
2.19 – 2.24 (m, 1 H), 1.87 (t, J = 12.9 Hz, 1 H), 1.70 – 1.79 (m, 1 H), 1.30 (t, J = 7.0 Hz, 
3 H), 1.24 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 167.0, 166.2, 151.9, 132.5, 119.4, 119.2, 107.2, 94.5, 
84.0, 67.7, 62.6, 62.3, 41.4, 34.1, 27.9, 14.0, 14.0. 
HRMS (m/z): 374.1480 (calcd for C19H22N2O6, 374.1478). 
 
Compound 1-98p 
The title compound was prepared according to the general cycloaddition procedure B at rt 
for 2 h to afford a yellow syrup (30 mg, 28%). 
Rf = 0.34 (30% EtOAc/hexanes). 
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1H NMR (600 MHz, CDCl3) δ 8.01 – 8.04 (m, 1 H), 7.55 – 7.60 (m, 1 H), 7.19 – 7.23 
(m, 1 H), 6.75 – 6.79 (m, 1 H), 5.58 (d, J = 4.7 Hz, 1 H), 4.22 – 4.32 (m, 2 H), 4.19 (q, J 
= 7.0 Hz, 1 H), 4.10 – 4.17 (m, 1 H), 3.93 (q, J = 8.0 Hz, 1 H), 2.68 – 2.77 (m, 2 H), 2.53 
– 2.60 (m, 1 H), 1.98 – 2.10 (m, 2 H), 1.22 – 1.27 (m, 3 H), 1.13 – 1.17 (m, 3 H). 
13C NMR (101 MHz, CDCl3) δ 168.9, 168.7, 159.3, 145.6, 137.5, 116.7, 109.8, 104.1, 
69.9, 69.1, 62.0, 61.6, 36.1, 31.8, 27.6, 13.8, 13.7. 
HRMS (m/z): 350.1470 (calcd for C17H22N2O6, 350.1478). 
 
Compound 1-98q 
The title compound was prepared according to the general cycloaddition procedure B, 
employing MgI2 (10 mol %) at rt for 4 h to afford a pale yellow oil (28 mg, 19%). 
Rf = 0.29 (30% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.6 Hz, 1 H), 7.52 (d, J = 3.5 Hz, 1 H), 7.50 
(d, J = 2.3 Hz, 1 H), 7.26 (dd, J = 9.0, 2.3 Hz, 1 H), 6.47 (d, J = 3.5 Hz, 1 H), 5.60 (d, J = 
5.5 Hz, 1 H), 3.94 – 4.28 (m, 6 H), 2.64 – 2.77 (m, 2 H), 2.51 – 2.62 (m, 1 H), 2.02 – 2.13 
(m, 1 H), 1.92 – 2.02 (m, 1 H), 1.65 (s, 9 H), 1.12 (t, J = 7.0 Hz, 3 H), 1.04 (t, J = 7.0 Hz, 
3 H). 
13C NMR (101 MHz, CDCl3) δ 169.0, 168.9, 142.9, 130.1, 126.1, 118.0, 114.1, 112.9, 
107.5, 104.5, 83.4, 74.4, 68.8, 62.0, 61.6, 35.3, 32.6, 29.0, 28.2, 13.8, 13.7. 
HRMS (m/z): 488.2153 (calcd for C25H32N2O8, 488.2159). 
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Compound 1-108aa 
The title compound was prepared according to the general cycloaddition procedure A for 
4 h to afford a pale yellow solid (50 mg, 45%). 
Rf = 0.25 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 7.22 – 7.31 (m, 4 H), 7.00 (t, J = 7.0 Hz, 1 H), 4.88 (d, J = 
2.9 Hz, 1 H), 4.26 – 4.33 (m, 2 H), 4.14 – 4.26 (m, 2 H), 4.04 – 4.10 (m, 1 H), 3.50 (td, J 
= 11.7, 1.8 Hz, 1 H), 2.42 – 2.49 (m, 1 H), 2.22 – 2.35 (m, 2 H), 1.87 – 1.95 (m, 1 H), 
1.76 – 1.86 (m, 2 H), 1.31 (t, J = 7.0 Hz, 3 H), 1.16 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 168.0, 166.9, 146.6, 128.5, 122.9, 117.4, 84.4, 67.9, 62.1, 
61.8, 29.9, 28.5, 27.5, 20.1, 14.1, 14.0. 
HRMS (m/z): 363.1688 (calcd for C19H25NO6, 363.1682). 
 
Compound 1-110an 
The title compound was prepared according to the general cycloaddition procedure B to 
afford a pale brown solid (40 mg, 35%). 
Rf = 0.26 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 6.90 – 6.94 (m, 2 H), 6.72 – 6.77 (m, 2 H), 5.03 (d, J = 
3.5 Hz, 1 H), 4.15 – 4.25 (m, 4 H), 3.90 – 3.96 (m, 1 H), 3.73 (s, 3 H), 3.44 (td, J = 11.3, 
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2.1 Hz, 1 H), 2.84 (t, J = 12.3 Hz, 1 H), 2.43 (dd, J = 12.0, 6.8 Hz, 1 H), 2.33 – 2.40 (m, 1 
H), 1.85 – 1.94 (m, 1 H), 1.69 – 1.80 (m, 2 H), 1.38 – 1.44 (m, 1 H), 1.22 (t, J = 7.0 Hz, 3 
H), 1.16 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 171.1, 153.3, 137.8, 118.0, 113.8, 90.0, 74.0, 63.9, 61.7, 
61.7, 55.5, 38.2, 35.1, 23.7, 20.7, 14.0, 13.9. 
HRMS (m/z): 377.1837 (calcd for C20H27NO6, 377.1838). 
 
Compound 1-110ao 
The title compound was prepared according to the general cycloaddition procedure B for 
1 h, followed by 1 h at rt to afford a yellow oil (22 mg, 19%). 
Rf = 0.43 (50% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 6.92 – 6.96 (m, 2 H), 6.65 – 6.68 (m, 2 H), 5.01 (d, J = 
4.1 Hz, 1 H), 4.15 – 4.21 (m, 4 H), 3.92 (d, J = 11.2 Hz, 1 H), 3.42 (td, J = 11.0, 2.1 Hz, 1 
H), 2.82 (s, 6 H), 2.39 – 2.44 (m, 1 H), 2.33 – 2.39 (m, 1 H), 1.83 – 1.93 (m, 1 H), 1.68 – 
1.80 (m, 2 H), 1.37 – 1.43 (m, 1 H), 1.24 – 1.30 (m, 1 H), 1.21 (t, J = 7.3 Hz, 3 H), 1.15 
(t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 171.4, 170.4, 145.5, 135.5, 118.9, 114.3, 90.2, 74.1, 63.8, 
61.6, 61.5, 41.8, 38.1, 35.2, 23.8, 20.8, 14.0, 13.9. 
HRMS (m/z): 390.2167 (calcd for C21H30N2O5, 390.2155). 
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Compound 1-108ga 
The title compound was prepared according to the general cycloaddition procedure A for 
15 min to afford a pale yellow oil (85 mg, 73%). 
Rf = 0.59 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 7.18 - 7.24 (m, 4 H), 6.98 - 7.01 (m, 1 H), 4.11 - 4.22 (m, 
4 H), 3.13 (s, 3 H), 2.60 (t, J = 12.6 Hz, 1 H), 2.14 (dd, J = 12.6, 3.8 Hz, 1 H), 1.95 - 2.00 
(m, 1 H), 1.66 - 1.75 (m, 2 H), 1.60 - 1.65 (m, 1 H), 1.43 - 1.48 (m, 2 H), 1.21 - 1.35 (m, 
3 H), 1.12 - 1.18 (m, 6 H). 
13C NMR (101 MHz, CDCl3) δ 168.8, 167.9, 148.8, 127.6, 123.3, 120.5, 101.4, 76.3, 
62.1, 61.0, 48.1, 40.6, 33.8, 29.3, 27.6, 25.5, 22.5, 13.9, 13.7. 
HRMS (m/z): 391.1987 (calcd for C21H29NO6, 391.1995). 
 
Compound 1-108gc 
The title compound was prepared according to the general cycloaddition procedure A to 
afford a pale yellow oil (90 mg, 70%). 
Rf = 0.65 (30% EtOAc/hexanes). 
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1H NMR (600 MHz, CDCl3) δ 7.16 (s, 4 H), 4.11 - 4.23 (m, 4 H), 3.10 (s, 3 H), 2.58 (t, J 
= 12.6 Hz, 1 H), 2.12 (dd, J = 12.6, 3.8 Hz), 1.93 – 1.99 (m, 1 H), 1.60 - 1.75 (m, 3 H), 
1.42 - 1.52 (m, 3 H), 1.26 - 1.36 (m, 1 H), 1.19 - 1.26 (m, 1 H), 1.14 - 1.19 (m, 6 H). 
13C NMR (101 MHz, CDCl3) δ 168.6, 167.8, 147.5, 127.6, 122.0, 101.6, 76.4, 62.2, 61.2, 
48.0, 40.6, 33.7, 29.3, 27.6, 25.5, 22.5, 14.0, 13.7. 
HRMS (m/z): 425.1607 (calcd for C21H28ClNO6, 425.1605). 
 
Compound 1-108fa 
The title compound was prepared according to the general cycloaddition procedure A to 
afford a yellow oil (29 mg, 21%). 
Rf = 0.40 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 7.16 – 7.24 (m, 4 H), 6.99 – 7.03 (m, 1 H), 5.03 (dd, J = 
7.9, 3.8 Hz, 1 H), 4.19 – 4.25 (m, 2 H), 4.11 – 4.19 (m, 2 H), 3.94 (dq, J = 9.9, 7.1 Hz, 1 
H), 3.61 (dq, J = 9.9, 7.1 Hz, 1 H), 2.58 (dt, 13.5, 4.7 Hz, 1 H), 2.44 (ddd, 13.4, 12.2, 4.4 
Hz, 1 H), 1.97 (dq, J = 13.4, 4.2 Hz, 1 H), 1.76 – 1.84 (m, 1 H), 1.22 (t, J = 7.0 Hz, 3 H), 
1.18 (t, J = 7.0 Hz, 3 H), 1.13 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 168.4, 168.1, 148.3, 127.7, 123.3, 119.5, 102.5, 74.8, 
64.7, 61.9, 61.6, 30.8, 27.0, 15.1, 13.8, 13.7. 
HRMS (m/z): 351.1679 (calcd for C18H25NO6, 351.1682). 
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Compound 1-109fn 
The title compound was prepared according to the general cycloaddition procedure B to 
afford a yellow oil (43 mg, 38%). 
Rf = 0.36 (30% EtOAc/hexanes) 
1H NMR (600 MHz, CDCl3) δ 7.19 – 7.23 (m, 2 H), 6.75 – 6.79 (m, 2 H), 5.00 (dd, J = 
8.2, 3.5 Hz, 1 H), 4.06 – 4.23 (m, 4 H), 3.83 – 3.90 (m, 1 H), 3.77 (s, 3 H), 3.53 – 3.60 
(m, 1 H), 2.57 (dt, J = 13.5, 4.7 Hz, 1 H), 2.44 (td, J = 12.6, 4.7 Hz, 1 H), 1.95 (dq, J = 
13.4, 4.2 Hz, 1 H), 1.73 – 1.83 (m, 1 H), 1.17 – 1.22 (m, 6 H), 1.13 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 168.3, 168.1, 156.4, 141.3, 122.7, 112.8, 102.3, 75.2, 
64.6, 61.8, 61.5, 55.4, 27.1, 37.7, 15.1, 13.9, 13.8. 
HRMS (m/z): 381.1778 (calcd for C19H27NO7, 381.1788). 
 
Compound 1-111fn 
To a stirred solution of MgI2 (47 mg, 0.17 mmol) in 6 mL CH2Cl2 at rt was added 1-
109fn (130 mg, 0.34 mmol). The RM was stirred for about 30 min at rt (complete 
consumption of starting material by TLC) then the RM was layered directly onto a silica 
gel column and purified by flash chromatography (0-25% EtOAc/hexanes) to afford a 
yellow oil (50 mg, 38%). 
Rf = 0.43 (30% EtOAc/hexanes). 
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1H NMR (400 MHz, CDCl3) δ 6.70 - 6.75 (m, 2 H), 6.58 - 6.64 (m, 2 H), 4.81 (s, 1 H), 
4.16 - 4.26 (m, 4 H), 4.04 (q, J = 7.2 Hz, 2 H), 3.73 (s, 3 H), 2.61 - 2.68 (m, 2 H), 2.22 - 
2.29 (m, 2 H), 1.19 (t, J = 7.0 Hz, 9 H). 
13C NMR (101 MHz, CDCl3) δ 196.3, 172.7, 169.6, 153.2, 137.6, 116.9, 114.6, 68.1, 
62.4, 60.5, 55.6, 28.7, 27.4, 14.1, 13.9. 
HRMS (m/z): 381.1789 (calcd for C19H27NO7, 381.1788). 
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1.4.3 Cascade Reaction of Donor-Acceptor Cyclopropanes: Mechanistic Studies in 
Cycloadditions with Nitrosoarenes and cis-Diazenes 
Majority of the experimental work done by Tristan Chidley (M.Sc. 2015) and only 
representative examples are shown in here.88 
 
Compound 1-124aa 
To a solution of cyclopropane 1-122a (100 mg, 0.43 mmol) and nitrosobenzene (1-96a, 
21 mg, 0.20 mmol) in (CH2)2Cl2 (3 mL) at rt was added Yb(OTf)3·H2O (12 mg, 0.02 
mmol) and stirred for about 15 min. The RM was then heated to reflux until compete 
consumption of nitrosobenzene (3 h, as indicated by TLC). Then the RM was cooled to rt 
and directly layered onto a silica gel column and purified by flash chromatography (0-
10% EtOAc/hexanes) to afford the title compound as a yellow oil, which was 
recrystallized with CH2Cl2/hexanes to give a white solid (75 mg, 87%). The 
characterization data is in agreement with literature values.89  
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Crossover Experiment 1 
 
To a solution of cyclopropanes 1-122a (0.43 mmol, 1.0 equiv), 1-122b (0.43 mmol, 1.0 
equiv) and nitrosobenzene (1-96a, 0.43 mmol, 1.0 equiv) in (CH2)2Cl2 (3 mL) was added 
Yb(OTf)3·H2O (0.02 mmol, 0.1 equiv) and stirred for 15 min. The mixture was then 
refluxed for about 22 h. After compete consumption of nitrosobenzene (as indicated by 
TLC) the RM was directly layered onto a silica gel column and isolated all 4 compounds 
in pure form by flash chromatography (0-10% EtOAc/hexanes). 
These 4 isolated compounds are identical with the standards independently synthesized 
from literature methods.90 
 
Compound 1-124bb 
The title compound was isolated in crossover experiment 1 as yellow oil, which was 
recrystallized with CH2Cl2/hexanes to give a white solid (73 mg, 35%).  
Rf = 0.58 (25% EtOAc/hexanes). 
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1H NMR (400 MHz, CDCl3) δ 7.43 - 7.49 (m, app dd, J = 8.2, 6.6 Hz, 4 H), 7.27 (app d, 
J = 8.2 Hz, 2 H), 7.07 - 7.17 (m, 4 H), 6.98 (d, J = 8.2 Hz, 2 H), 6.80 (app tt, J = 7.0, 1.6 
Hz, 1 H), 5.76 (s, 1 H), 4.99 (dd, J = 12.1, 2.3 Hz, 1 H), 4.38 (q, J = 7.0 Hz, 2 H), 3.84 – 
4.02 (app dddd, J = 7.0, 7.0, 7.0, 10.5 Hz, 2 H), 2.87 (app dd, J = 14.5, 12.5 Hz, 1 H), 
2.75 (app dd, J = 14.5, 2.3 Hz, 1 H), 2.41 (s, 3 H), 2.22 (s, 3 H), 1.35 (t, J = 7.0 Hz, 3 H), 
1.06 (t, J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 169.7, 168.0, 148.7, 138.1, 137.5, 136.6, 131.9, 130.4, 
129.2, 128.6, 128.5, 126.5, 121.3, 115.7, 78.7, 65.4, 62.2, 61.7, 59.4, 31.6, 21.2, 21.0, 
14.2, 13.7. 
HRMS (m/z): 487.2348 (Calcd for C30H33NO5, 487.2359). 
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1.4.4 Cycloadditions of Donor-Acceptor Cyclobutanes and cis-Diazenes 
Known AACDs 1-53a – 1-53f were prepared according to literature procedures.38 
 
Compound 1-67l 
Following a reported procedure,38 to a stirring solution of Yb(OTf)3·H2O (415 mg, 0.05 
equiv) in CH2Cl2 (25 mL) at rt was slowly added, a cold solution (maintained at –78 °C) 
of 1-methoxycyclohept-1-ene91 (2.0 g, 15.85 mmol, 1.2 equiv), and diethyl 2-
methylenemalonate (2.3 g, 13.36 mmol, 1.0 equiv) in CH2Cl2 (25 mL). After addition, the 
RM was stirred until appeared complete by TLC (~30 min). Pyridine (1 mL) was added 
and the reaction was filtered through a bilayer pad of silica gel (2 cm) and Celite® (1 cm) 
open to the atmosphere. The filtrate was concentrated in vacuo and the residue was 
purified by silica gel flash chromatography (0-5% EtOAc/hexanes, buffered with 1% 
Et3N) to afford the title compound as a colorless oil (1.60 g, 40%).  
Rf = 0.41 (20% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 4.21 (dq, J = 14.3, 7.2 Hz, 4 H), 3.27 (s, 3 H), 2.63 - 2.75 
(m, 1 H), 2.43 - 2.55 (m, 2 H), 2.00 (dt, J = 13.9, 7.1 Hz, 1 H), 1.75 - 1.85 (m, 1 H), 1.63 
- 1.74 (m, 2 H), 1.54 - 1.63 (m, 1 H), 1.34 - 1.52 (m, 2 H), 1.25 - 1.32 (m, 6 H), 1.08 - 
1.25 (m, 3 H). 
13C NMR (101 MHz, CDCl3) δ 169.6, 87.0, 61.4, 60.8, 60.3, 50.8, 43.0, 31.7, 28.5, 27.9, 
26.1, 24.3, 23.3, 14.1, 14.0. 
HRMS (m/z): 298.1792 (calcd for C16H26O5, 298.1780). 
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The [4+2] cycloadditions of AACDs with cis–diazene (PTAD) were performed by 
Tristan Chidley (M.Sc. 2015) and only a representative example is shown in here.88 
 
Compound 1-136b 
To a solution of cyclobutane 1-67b (141 mg, 0.58 mmol, 2.0 equiv) and PTAD (1-30a,50 
mg, 0.29 mmol, 1.0 equiv) in (CH2)2Cl2 (3 mL) at rt was added a solution of GaCl3 (2.6 
mg, 0.015 mmol, 0.05 equiv) in (CH2)2Cl2 (0.5 mL) and stirred for about 30 min. Then 
the RM directly loaded onto a SiO2 column and was purified by flash chromatography 
(30-50% EtOAc/hexanes) to afford the title compound as a white solid. (111 mg, 92%).  
Rf = 0.50 (50% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) 7.45 - 7.53 (m, 4 H), 7.38 (app t, J = 7.0 Hz, 1 H), 5.78 (d, J 
= 4.3 Hz, 1 H), 4.29 - 4.37 (m, 4 H), 4.18 - 4.23 (m, 2 H), 4.08 (td, J = 9.4, 2.0 Hz, 1 H), 
2.64 (dd, J = 13.3, 5.9 Hz, 1 H), 2.40 - 2.48 (m, 1 H), 2.28 - 2.36 (m, 1 H), 2.24 (dd, J = 
13.3, 12.1 Hz, 1 H), 1.90 (ddd, J = 6.6, 6.6, 2.0 Hz, 1 H), 1.34 (t, J = 7.0 Hz, 3 H), 1.32 (t, 
J = 7.0 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) 166.2, 165.8, 153.7, 151.0, 131.0, 129.1, 128.3, 125.7, 
77.6, 70.4, 65.0, 63.2, 63.0, 26.5, 25.6, 15.0, 14.1, 13.8. 
HRMS (m/z):  417.1530 (Calcd for C20H23N3O7, 417.1536). 
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1.4.5 Spiroketals from AACDs 
 
Compound 1-143a 
To a stirring solution of Zn(OTf)2 (216 mg, 0.05 equiv) in CH2Cl2 (10 mL) at -78 °C was 
simultaneously added (over 1 h), a rt solution of 2-methylenetetrahydrofuran (1.0 g, 
11.89 mmol, 1.0 equiv) in CH2Cl2 (3 mL) and diethyl 2-methylenemalonate (3.1 g, 17.83 
mmol, 1.5 equiv) in CH2Cl2 (3 mL). After addition, the RM was stirred for about 15 min, 
and pyridine (0.3 mL) was added. Stirring was continued for 5 more min, then RM was 
filtered through a bilayer pad of silica gel (2 cm) and Celite® (1 cm) open to the 
atmosphere and the filtrate was concentrated in vacuo. After two unsuccessful attempts to 
purify the residue by flash column chromatography on silica gel (0-1% EtOAc/hexanes, 
buffered with 2% Et3N), the partially purified compound carried forward to next step 
without characterization. 
 
Compound 1-145a 
To a solution of Yb(OTf)3·H2O (29 mg, 0.04 mmol, 0.1 equiv) in CH2Cl2 (1 mL) at 0 °C 
was added benzaldehyde (145 mg, 0.57 mmol, 1.0 equiv) followed by cyclobutane 1-
143a (50 mg, 0.47 mmol, 1.2 equiv). After 15 min the RM passed through a plug of silica 
gel (2 cm), washed with CH2Cl2 (5 mL), and the solvent concentrated in vacuo to obtain 
the title compound as a colorless oil in a reasonably pure form (77 mg, 45%).  
Rf = 0.24 (20% EtOAc/hexanes). 
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1H NMR (600 MHz, CDCl3) δ 7.43 (d, J = 7.0 Hz, 2 H), 7.19-7.25 (m, 3 H), 5.50 (s, 1 
H), 4.14 (q, J = 7.4 Hz, 2 H), 4.01 (dq, J = 10.9, 7.1 Hz, 1 H), 3.91 (td, J = 8.2, 5.9 Hz, 1 
H), 3.79-3.85 (m, 2 H), 2.39-2.45 (m, 2 H), 2.30-2.36 (m, 1 H), 2.09-2.16 (m, 1 H), 1.98-
2.06 (m, 1 H), 1.82-1.90 (m, 1 H), 1.71-1.80 (m, 2 H), 1.16 (t, J = 7.3 Hz, 3 H), 0.93 (t, J 
= 7.3 Hz, 3 H). 
13C NMR (101 MHz, CDCl3) δ 170.9, 169.1, 139.9, 127.6 (2 C), 127.1, 127.0 (2 C), 
106.2, 73.4, 67.4, 61.1, 60.4, 58.2, 37.4, 29.1 (2 C), 23.5, 13.9, 13.5. 
HRMS (m/z): 385.1612 (calcd for C20H26O6 + Na, 385.1627). 
 
Compound 1-149a 
The title compound was isolated as a byproduct in [2+2] cycloaddition reaction.  
Rf = 0.43 (30% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 4.18 (app qd, J = 7.0, 1.6 Hz, 6 H), 4.07 (t, J = 6.8 Hz, 1 
H), 3.40 (t, J = 7.6 Hz, 1 H), 2.63 (app t, J = 7.6 Hz, 2 H), 2.45 (td, J = 7.5, 1.4 Hz, 2 H), 
2.93 (quin, J = 7.1 Hz, 2 H), 1.25 (t, J = 7.0 Hz, 6 H). 
13C NMR (101 MHz, CDCl3) δ 169.3, 157.1, 90.3, 70.5, 61.0, 52.3, 28.8, 24.8, 24.8, 
14.0. 
HRMS (m/z): 256.1310 (calcd for C13H20O5, 256.1311). 
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2 Chapter 2. Studies Towards the Synthesis of Streptorubin B 
This chapter describes synthetic efforts towards the prodigiosin alkaloid streptorubin B 
using our group developed [3+2] cycloaddition of DA cyclopropanes and nitriles. An 
overview of this methodology along with relevant background information as well as 
reported studies directed towards the synthesis of streptorubin B and related prodigiosins 
has been discussed.  
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2.1 Introduction  
The prodigiosin family of alkaloids have been of interest to both chemists and biologists 
for their unique molecular architecture and range of biological properties.1 Even though, 
prodigiosins share a common tripyrrole skeleton, they are diverse in molecular 
connectivity (Figure 2-1).2 Some of them have unique pyrrolophane core structure (such 
as 2-1) and some are distinctive macrocycles (such as 2-2). They display a characteristic 
deep-red color which has been misinterpreted in certain religious or symbolic contexts as 
the miraculous appearance of blood in certain foods.2b 
 
Figure 2-1. Representative members of prodigiosin family of alkaloids. 
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2.1.1 Biological Activity of Prodigiosins 
The natural prodigiosins have impressive array of biological activities,3 and have inspired 
many medicinal chemists to synthesize hundreds of structural congeners for their 
potential as active ingredients in immunosuppressant and anti-cancer therapeutics.4   As a 
result of these studies, Pharmacia-Upjohn discovered a synthetic congener PNU156804 
(2-7, Figure 2-2), which had impressive immunosuppressive properties, and was selected 
as a drug candidate for further studies.5 Gemin X (which was later acquired by Cephalon) 
discovered Obatoclax (2-8, Figure 2-2) for the treatment of various types of cancers, 
which is currently in Phase II clinical trials for the treatment of leukemia, lymphoma, 
myelofibrosis, and mastocytosis.6 
 
Figure 2-2. Structures of PNU156804 (2-7) and Obatoclax (2-8). 
2.1.2 Streptorubin B 
Streptorubin B (2-1) was first isolated in 1964 by Thirumalachar and co-workers from 
Streptomyces caespitosus bacteria, found in soil samples in Pimpri, India.7 In 1975, 
Gerber and co-workers reported isolation of a red pigment from Streptomyces sp. Y-42 
and Streptomyces abikoensis, which was structurally assigned as 
butylcycloheptylprodigiosin (2-3).8 Due to the structural similarities between 2-1 and 2-3, 
which differ only in connectivity of the pyrrole ring, there was confusion regarding the 
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structures of these compounds. Later in 1978, Gerber expressed the need to revise the 
structure of 2-3 to 2-1 without elaborating the reasons behind this revision.9 A few years 
later, in 1985, Floss and co-workers assigned the structure of 2-3 to a pink pigment 
isolated from a strain of Streptomyces coelicolor.10 In 1991, Weyland and co-workers 
reported the isolation of a red pigment from an actinomycete strain B 4358, which was 
assigned as 2-1 based on 2D NMR data.11 Weyland also stated that the assignment of 2-3 
assigned by Gerber and Floss should be revised to 2-1. In 2005, Fürstner reported the 
synthesis of 2-3,12 followed by Reeves in 2007,13 who stated 2-3 is in fact the natural 
product isolated by Gerber and Floss, against Weyland claims. Futhermore, in 2008, 
Challis and co-workers isolated 2-1  from Streptomyces coelicolor, the organism from 
which Floss isolated red pigment, and they found no evidence for the production of 2-3.14 
The debate was continued until 2013, when Thomson and co-workers conducted mass 
spectral analysis and proposed biosynthesis hypotheses to eliminate 
butylcycloheptylprodigiosin (2-3) as a known natural product.15 The compound Floss 
isolated from Streptomyces coelicolor and Gerber from Streptomyces sp. Y-42 and 
Streptomyces abikoensis was in fact streptorubin B (2-1). 
From a synthetic chemist point of view, streptorubin B (2-1) is very interesting 
target for its unique 10-membered 2,4-pyrrolophane structure with possible 
atropisomerism16 and its potent cytotoxicity against tumor cells,30 it has been shown to 
selectively kill 100% breast cancer cells at 1 µM doses.17  
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2.1.3 Biosynthesis of Streptorubin B and Related Prodigiosins 
It was widely accepted that a key step in the biosynthesis of the prodigiosins is the non-
enzymatic condensation of 4-methoxy-2,2'-bipyrrole-5-carboxaldehyde (2-9) with a 
substituted pyrrole moiety 2-10 (Scheme 2-1).2 
 
Scheme 2-1. Biosynthesis of the prodigiosins from condensation of aldehyde 2-9 with 
pyrrole 2-10. 
Biosynthetic studies including 13C labelled feeding studies established that each 
pyrrole was derived in a series of enzymatic reactions from different amino acids and 
alkyl chains formed from several acetyl units.18  
From a structural standpoint, streptorubin B (2-1) and streptorubin A (2-5, widely 
known as metacycloprodigiosin) are very similar (Figure 2-3). It was understood that 
these highly strained pyrrolophane natural products were formed by oxidative ring 
closure mediated by Rieske oxygenase-like enzymes from a common intermediate, 
undecylprodigiosin (2-12).19 This biosynthesis proposal was supported by the fact that 
undecylprodigiosin (2-12) has been isolated from the same strains of bacteria as 
metacycloprodigiosin (2-5) and streptorubin B (2-1).8a, 9 
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Figure 2-3. Biosynthesis of streptorubin B (2-1) and streptorubin A (2-5) from 
undecylprodigiosin (2-12) catalyzed by enzymes RedG and McpG respectively. 
2.1.4 Published Studies Towards the Streptorubin B and Related Prodigiosins 
There have been many synthetic studies reported towards aldehyde 2-9. The first 
successful synthesis of aldehyde 2-9 was reported by Rapoport and co-workers in 1962.20 
Rapoport’s synthesis of aldehyde 2-9 was straightforward, consisting of seven linear 
steps (Scheme 2-2). The synthesis began with the condensation of ethyl N-
(ethoxycarbonyl)glycinate (2-13) with diethyl ethoxymethylenemalonate (2-14) followed 
by conversion of the resulting alcohol 2-15 to methyl ether 2-16  with diazomethane. 
Selective dealkoxy-carbonylation with H2SO4 and heat followed by condensation with 1-
pyrroline (2-18) led to pyrrolidinylpyrrole 2-19 which was dehydrogenated to 2,2'-
bipyrrole 2-20. Bipyrrole ester 2-20 was then converted to the corresponding aldehyde 2-
9 under McFadyen-Stevens conditions. Acid catalyzed condensation of this aldehyde 
with 2-methyl-3-pentylpyrrole (2-21, which was made in five steps from 3-octanone) 
resulted in synthetic prodigiosin (2-4). 
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Scheme 2-2. Rapoport's synthesis of prodigiosin (2-4). 
In 2004, Wasserman and co-workers reported a short synthesis of aldehyde 2-9. 
The report described the synthesis of the tert-butyl analogue 2-25 (Scheme 2-3) of 
Rapoport’s intermediate 2-20 via addition of singlet oxygen to certain pyrrole compounds 
(Scheme 2-3).21 The transient imino hydroperoxide intermediate 2-23 has been shown to 
react with a number of nucleophiles, such as pyrrole to give 2,2'-bipyrrole 2-25. 
Subsequent McFadyen-Stevens reduction produced aldehyde 2-9 (see Scheme 2-2). 
109 
 
Although this route allows for the structural modifications on the pyrrole, it is limited by 
the low yields of both the singlet oxygen reaction as well as the McFadyen-Stevens 
reduction. 
 
Scheme 2-3. Wasserman's singlet oxygen methodology for the synthesis of aldehyde 2-9. 
In 2006, Lavallèe and Tripathy reported the shortest synthesis of aldehyde 2-9 to 
date.22 Commercially available 4-methoxy-3-pyrolin-2-one (2-26) was treated with the 
Vislmeier–Haack reagent derived from diethylformamide23 to produce bromopyrrole 
enamine 2-27 in 70% yield. Suzuki cross-coupling reaction of 2-27 with N-Boc-2-
pyrroleboronic acid (2-28) followed by aq work-up led to the aldehyde 2-9 in 95% yield 
(Scheme 2-4). Furthermore, the authors applied this methodology towards the efficient 
synthesis of Obatoclax (2-8).24 
 
Scheme 2-4. Lavallèe and Tripathy's synthesis of aldehyde 2-9. 
The first total synthesis of metacycloprodigiosin (2-5) was reported by 
Wassermann and co-workers in 1969, following its isolation and structural 
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determination.25 As described in Scheme 2-5, the synthesis began with enolate ethylation 
of 2-29 followed by protection of the carbonyl as spiroketal 2-30 in a 32% yield. 
Regioselective bromination followed by E2 elimination with DBU establishes enone 2-31 
in a 91% yield. Deprotection of the carbonyl, epoxidation, followed by acidic hydrazine-
promoted rearrangement of α,β-epoxyketone to allylic alchol 2-32 was achieved in 30% 
yield. Oxidation of alcohol 2-32 followed by 1,4-addition of cyanide to the resulting 
enone was accomplished in 91% yield. Protection of the ketone followed by DIBAL-H 
reduction of nitrile 2-33 led to aldehyde 2-34. Deprotection of the ketone followed by 
Paal-Knorr cyclization with ammonium carbonate completed the synthesis of pyrrole 2-
35 in 3.5% overall yield over 13 linear steps. This pyrrole moiety was then condensed 
with the known aldehyde 2-9 to complete the synthesis of metacycloprodigiosin (2-5).  
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Scheme 2-5. Wasserman's total synthesis of metacycloprodigiosin (2-5). 
A few years later, in 1998, Fürstner and co-workers reported an efficient synthesis 
of the pyrrolophane core (2-35) of metacycloprodigiosin (2-5) via enyne metathesis.26 
As depicted in Scheme 2-6, the synthesis began with an ene-type reaction on the 
cyclodecene (2-36) with an in situ generated diiminoselenium reagent.27 Alkylation of 
allyl amine 2-37 with propargyl bromide, and a subsequent acylation of the resulting 
terminal alkyne 2-38 with acetyl chloride established the enyne 2-39 required for the 
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metathesis reaction. The enyne metathesis reaction28 on 2-39 was initiated with either 
BF3·OEt2 or PtCl2 to afford ring-expanded product 2-40 in moderate yield. The enone of 
bicycle 2-40 was reduced to 2° alcohol 2-41, which was thionylated with O-Phenyl 
chlorothionoformate followed by Barton-McCombie dehydroxylation to give 2-43. 
Compound 2-43 was then converted into pyrrolophane 2-35 by a one pot detosylation and 
aromatization with potassium 3-aminopropylamide (KAPA).29 Thus, the formal synthesis 
of metacycloprodigiosin 2-5 was achieved in 5% overall yield from commercially 
available cyclodecene. 
 
Scheme 2-6. Fürstner's synthesis of Wasserman’s pyrrole 2-35 via enyne metathesis. 
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The first synthesis of the pyrrolophane core (2-52) of streptorubin B (2-1) was 
accomplished by the Fürstner group (Scheme 2-7).26 The required precursor 2-47 for the 
enyne metathesis reaction was prepared from cyclooctene by a series of transformations 
similar to those discussed earlier (vide supra). The PtCl2-catalyzed enyne metathesis 
reaction on 2-47 resulted in ring expanded product 2-48 in 94% yield, which was then 
converted into pyrrolophane 2-52 through previously described transformations. Thus, 
the first synthesis of pyrrolophane core (2-52) of streptorubin B (2-1) was achieved in 
about 16% overall yield in nine steps from cyclooctene. 
 
Scheme 2-7. Fürstner’s first synthesis of pyrrolophane core (2-52) of                     
streptorubin B (2-1). 
In an effort to synthesize a library of prodigiosin derivatives for drug discovery, 
Murthy and co-workers completed the first total synthesis of streptorubin B along with 
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several structural congeners using Fürstner’s route.30 They used chiral catalyst 
Ru2Cl4((S)-BINAP)2(NEt3) to reduce the ketone 2-49 to a pair of alcohols 2-50a and 2-
50b, which were separated and carried on independently according to Fürstner’s route to 
pyrrolophanes 2-52a and 2-52b (Scheme 2-8). These pyrrolophanes were then condensed 
independently with the known aldehyde 2-9 to access both enantiomers of streptorubin B.   
 
Scheme 2-8. Murthy's asymmetric syntheses of both enantiomers of streptorubin B. 
In 2005, Chang and co-workers reported a synthesis of intermediate 2-51 using 
ring closing metathesis (RCM).31 The synthesis began with the commericially available 
trans-4-hydroxy-L-proline (2-53). Esterificaton of the acid and tosylation of the amine 
followed by silylation of the 2° alcohol and reduction of the ester resuted in prolinol 2-55 
in 90% yield over four steps. Swern oxidation, Wittig reaction on the resulting aldehyde, 
followed by two reductions gave 1° alcohol 2-57. Oxidation of this alcohol by PCC, 
followed by Wittig reaction installed the alkene required for the RCM reaction. 
Deprotection of the alcohol followed by PCC oxidation gave ketone 2-59. Grignard 
addition into this ketone followed by RCM with Grubbs II catalyst resulted in 2-62 as a 
115 
 
mixture of geometrical isomers and diastereomers. This mixture was then converted to 
Fürstner’s intermediate 2-51 by hydrogenation of the alkene followed by dehydration of 
the 3° alcohol.  
 
Scheme 2-9. Chang’s synthesis of Fürstner’s intermediate 2-51 of streptorubin B. 
Even though the total synthesis of the streptorubin B has been achieved, no 
comparison was made between synthetic and natural samples of streptorubin B to 
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establish the absolute and relative configuration. It was not until 2010 when the 
Thompson group established the correct absolute and relative stereochemistry of 
streptorubin B through an enantioselective total synthesis and comparisons of circular 
dichroism (CD) spectra.32 
As described in Scheme 2-10, the synthesis began with the oxidative cleavage of 
cycloheptene (2-63) to afford the dialdehyde necessary for an asymmetric intramolecular 
aldol reaction.33 An (S)-proline catalyzed aldol followed by Witting reaction with ylide 2-
66 gave the homoallylic alcohol 2-67 with high diastereocontrol. Oxidation of alcohol 2-
67 followed by addition of vinyl anion 2-68 installed the functional handles required for 
an anionic Cope rearrangement. Upon exposure of alcohol 2-69 to KHMDS and 18-
crown-6 produced the desired 10-membered ring in 85% yield with excellent 
stereochemical transfer. This cyclic ketone was then efficiently converted into pyrrole 2-
52a following reduction of the alkene with concomitant cleavage of the benzyl ether, 
Dess-Martin oxidation of the resulting alcohol, and Paal-Knorr pyrrole synthesis. Pyrrole 
2-52a was converted into streptorubin B (2-1) through an acid-promoted condensation 
with aldehyde 2-72, followed by deprotection of Boc group via basic methanolysis. 
Interestingly, the isolated product was a 10:1 mixture of two compounds of which the 
major compound is not the streptorubin B (possibly atropisomer of streptorubin B). 
However, over time (10 days), the mixture completely transformed into the natural 
product, making this route the shortest to date, in nine linear steps with 20% overall yield 
from cycloheptene (2-63). 
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Scheme 2-10. Thompson's enantioselective total synthesis of streptorubin B (2-1). 
In summary, the synthesis of streptorubin B (2-1) was achieved and its absolute 
and relative stereochemistry was firmly established with X-ray crystallography. The 
above discussed syntheses (and a few unsuccessful studies)34 are efficient in their own 
way, but they are linear and rather lengthy. Thus, a convergent approach to streptorubin 
B, which would also allow the expedited synthesis of structural congeners is warranted.  
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2.2 Project Plans and Goals 
Our goal for this project was to achieve the total synthesis of streptorubin B in a modular 
approach, which would allow for late stage functionalization. As shown in Scheme 2-11, 
the butyl side chain of the streptorubin B could be attained via a Wittig reaction followed 
by an asymmetric hydrogenation of compound 2-73.35 We envisioned the pyrrolophane 
core structure can be prepared via our group developed [3+2] cycloaddition between DA 
cyclopropanes and nitriles (see Section 2.3). Therefore, compound 2-73 can come from a 
Lewis acid catalyzed [3+2] cycloaddition of bicyclic DA cyclopropane 2-74 and 
functionalized nitrile 2-75. 
 
Scheme 2-11. Retrosynthesis of streptorubin B (2-1). 
The bicyclic DA cyclopropane 2-74 can be accessed from a known cyclononane-
1,3-dione (2-77)36 via enolate O-alkylation followed by cyclopropanation (Scheme 2-12). 
The cyclononane-1,3-dione (2-77) could be prepared from commercially available 
dimethyl octanedioate (2-80) using a known 3-step procedure36 via acyloin condensation 
of 2-80, followed by Simmons-Smith cyclopropanation and subsequent oxidative ring-
expansion. 
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Scheme 2-12. Retrosynthesis of bicyclic DA cyclopropane 2-74. 
One of the major advantages of this synthesis would be the ease of late stage 
functionalization. Also, this strategy, if ideally executed, could be a short synthesis of 
streptorubin B in five linear steps from a known 1,3-dione 2-77.  
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2.3 Cycloaddition of DA Cyclopropanes and Nitriles 
2.3.1 The [3+2] Cycloaddition of DA Cyclopropanes and Nitriles  
The first example of [3+2] cycloaddition between DA cyclopropanes and nitriles was 
reported by Pagenkopf and Yu in 2003.37 The report disclosed a novel TMSOTf-
promoted [3+2] cycloaddition of carbohydrate-derived DA cyclopropanes 2-81 with a 
wide range of nitriles 2-82 to produce 1-pyrrolines (2-83) in good to excellent yields 
(Scheme 2-13). 
 
Scheme 2-13. TMSOTf-promoted [3+2] cycloaddition of DA cyclopropanes and nitriles. 
A few years later, in 2010, Trushkov and co-workers extended this methodology 
to aryl-activated DA cyclopropanes.38 In this report, only alkyl nitriles were examined in 
cycloadditions with DA cyclopropanes under excess-stoichiometric SnCl4 conditions. 
The cycloaddition afforded 1-pyrrolines in good yields (Scheme 2-14). 
 
Scheme 2-14. SnCl4-promoted [3+2] cycloaddition of DA cyclopropanes and nitriles. 
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In 2011, Srinivasan and co-workers further extended Trushkov’s methodology to 
a highly activated DA cyclopropane 2-86 under stoichiometric SnCl4 conditions (Scheme 
2-15).39 Both alkyl and aryl nitriles were reported to undergo efficient cyclizations with 
DA cyclopropane 2-68 affording 1-pyrrolines in good yields.  
 
Scheme 2-15. SnCl4-promoted [3+2] cycloaddition of highly activated DA cyclopropane 
2-86 with nitriles. 
In an attempt to prepare enantiopure 1-pyrrolines via [3+2] cycloaddition of DA 
cyclopropanes and nitriles, Trushkov and co-workers subjected an enantiopure DA 
cyclopropane (S)-2-88 to previously reported cycloaddition conditions (see Scheme 
2-14). The reaction with acetonitrile (2-89) resulted in racemic 1-pyrroline 2-90 
suggesting that the reaction is going through an achiral zwitterionic intermediate 2-91 
(Scheme 2-16). Changing the solvent or temp did not help improve the stereoselectivity.  
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Scheme 2-16. SnCl4-promoted [3+2] cycloaddition of DA cyclopropane (S)-2-88 and 
acetonitrile (2-89). 
 Recently, Wang and co-workers reported a TfOH-promoted [3+2] cycloaddition 
of DA cyclopropanes with nitriles.40 The cycloaddition reported to have a broad substrate 
scope including aryl, allyl, or alkyl activated DA cyclopropanes with a wide range of 
nitriles (Scheme 2-17). 
 
Scheme 2-17. TfOH-promoted [3+2] cycloaddition of DA cyclopropanes with nitriles 
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2.3.2 Pyrroles from DA Cyclopropanes and Nitriles 
During the efforts to expand TMSOTf-promoted [3+2] cycloaddition of DA 
cyclopropanes and nitriles (see Scheme 2-13), Pagenkopf and Yu made an interesting 
observation. When the reaction was conducted in either toluene or dichloromethane, only 
rearranged products 2-95 and/or 2-96 were formed (eq 1, Scheme 2-18), but when highly 
polar solvents, such as nitromethane or nitroethane were used, the reaction underwent a 
tandem [3+2] cycloaddition, elimination, and tautomerization sequence to produce 
pyrroles 2-98 (eq 2, Scheme 2-18).41 
 
Scheme 2-18. The effect of solvent in reaction of DA cyclopropanes with nitriles. 
 Gratifyingly, this cascade reaction has a broad substrate scope (Table 2-1).42 A 
wide range of DA cyclopropanes, irrespective of the substitution around the ring, were 
found to undergo efficient cyclizations with a variety of nitriles in good to excellent 
yields (2-98a-2-98m). Interestingly, substrates with silyl protecting groups, were also 
tolerated by the reaction conditions to afford pyrroles (2-98n-2-98p).   
124 
 
Table 2-1. Pyrroles from DA cyclopropanes and nitriles. 
 
A year later, in 2004, Pagenkopf and co-workers applied this methodology 
towards the synthesis of unsymmetrical 2,2'-bipyrroles and 2,2'-thienylpyrroles.43 A 
series of DA cyclopropanes were reported to undergo cycloadditions with 2-
cyanopyrroles and 2-cyanothiophenes, to afford 2,2'-bipyrroles and 2,2'-thienylpyrroles, 
respectively (Table 2-2). 
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Table 2-2. Synthesis of 2,2'-bipyrroles and 2,2'-thienylpyrroles from cycloadditions of 
DA cyclopropanes and nitriles. 
 
 In 2010, Moustafa and Pagenkopf further developed this methodology towards 
the synthesis of 5-azaindoles via oxidation of the cycloadducts obtained through 
cycloadditions between functionalized DA cyclopropane 2-101 and nitriles (Scheme 
2-19).44 
 
Scheme 2-19. Synthesis of 5-azaindoles from DA cyclopropane 2-101 and nitriles. 
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2.3.3 Application in Total Synthesis 
Pagenkopf and co-workers demonstrated the utility of [3+2] cycloaddition of DA 
cyclopropanes and nitriles in their total syntheses of (±)-goniomitine (2-107)45 and (±)-
quebrachamine (2-108, Scheme 2-20).46 As shown in Scheme 2-20 the [3+2] 
cycloaddition of DA cyclopropane 2-104 with functionalized nitrile 2-105 (which was 
prepared from commercially available δ-valerolactam in 48% yield over 5 steps) afforded 
the pyrrole 2-106 in 74% yield. This pyrrole 2-106 was then converted into (±)-
goniomitine (2-107) in 11% yield over 10 steps. The pyrrole 2-106 was also transformed 
into (±)-quebrachamine (2-108) in 33% yield over 7 steps. Thus the syntheses of 
aspidosperma alkaloids (±)-goniomitine (2-107) and (±)-quebrachamine (2-108) were 
efficiently achieved via a [3+2] cycloaddition of DA cyclopropane 2-104 and nitrile 2-
105. 
 
Scheme 2-20. Total synthesis of (±)-goniomitine (2-107) and (±)-quebrachamine (2-108) 
via [3+2] cycloaddition of DA cyclopropane 2-104 and nitrile 2-105. 
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 In summary, cycloadditions of DA cyclopropanes with nitriles have been revealed 
to be an efficient method to prepare 1-pyrrolines. The diversity oriented synthesis of 
pyrroles via [3+2] cycloaddition, dehydration and tautomerization sequence, proved to be 
an excellent method with a broad substrate scope. The efficiency and practicality of this 
method has been shown in synthesis of 2,2'-bipyrroles, 2,2'-thienylpyrroles and 5-
azaindoles. Finally, this methodology has been showcased in the total synthesis of 
aspidosperma alkaloids (±)-goniomitine and (±)-quebrachamine. 
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2.4 General Introduction to Medium-sized Rings 
Molecules with medium-sized rings (MRs, 8-11 atoms)47 are present in a large number of 
biologically active natural products and are an important class of synthetic targets in drug 
discovery (Figure 2-4).48 
 
Figure 2-4. Representative examples of medium-sized rings in biologically important 
molecules. 
In contrast to larger rings (>11 atoms), the MRs have inherent strain associated 
with them.49 While Baeyer strain is predominant in small rings, transannular and Pitzer 
strains are severe in MRs compared to both smaller and larger rings.50 As shown in 
Figure 2-5, the measured experimental strain energies for MRs are quite high compared 
to other cycloalkanes (exempting cyclopropane and cyclobutane).51 
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Figure 2-5. Relative strain energies of cycloalkanes. 
(Energies are referenced to the chair-confirmation of cyclohexane at 0 Kcal/mol) 
The conformational properties of cyclooctane have been extensively studied, and 
it was revealed that the conformational preference for “boat-chair” at rt is the result of 
avoidance of unfavorable transannular interactions at the expense of Pitzer strain (Figure 
2-6).52  
 
Figure 2-6. Boat-chair conformation of cyclooctane (2-112, eclipsed bonds shown). 
Because of these unique structural features, any synthesis of MRs must overcome 
both enthalpic (increasing strain in the transition state) and entropic (probability of the 
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chain ends meeting) energy barriers. Thus the synthesis of MRs is relatively difficult 
compared to smaller or larger rings.53 
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2.5 Results and Discussion 
2.5.1 Attempted Synthesis DA Cyclopropane 2-74 
In order to attempt the proposed synthesis (see Scheme 2-11), we set out to 
synthesize cyclononane-1,3-dione (2-77). Following a reported synthesis,36 1,3-dione 2-
77 was prepared in ~25% yield over three steps from commercially available dimethyl 
octanedioate (2-80, Scheme 2-21). Acyloin condensation of 2-80 followed by trapping 
the intermediate with TMSCl afforded cyclooctene 2-79 in moderate yields. Furukawa 
modified Simmons-Smith cyclopropanation54 of 2-79 followed by oxidative ring 
expansion with FeCl3 afforded the cyclononane-1,3-dione (2-77).  
 
 
Scheme 2-21.  Synthesis of cyclononane-1,3-dione (2-77). 
 
Having 1,3-dione 2-77 at hand, O-methylation was attempted under TsOH 
catalyzed conditions. Disappointingly, 2-77 underwent a retro-Claisen reaction instead of 
O-methylation (Scheme 2-22). This could be due to the severe strain associated with the 
9-membered ring (see Section 2.4). 
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Scheme 2-22. Retro-Claisen condensation of 1,3-dione 2-77. 
We then examined base-mediated O-methylation with a variety of bases and 
methylating agents and were pleased to find KH and methyl Meerwein salt in DME 
afforded the vinylogous ester 2-76 in a 69% yield (Scheme 2-23).  After unsuccessful 
attempts at cyclopropanation of vinylogous ester 2-76, we decided to reduce the ketone to 
an alcohol prior to cyclopropanation. 
 
Scheme 2-23. O-Methylation of cyclononane-1,3-dione (2-77) 
 According to the revised plan (Scheme 2-24), the ketone of 2-76 was reduced to 
allylic alcohol 2-117 with LiAlH4 in excellent yield. Furukawa modified Simmons-Smith 
cyclopropanation of allylic alcohol resulted in bicyclic cyclopropyl alcohol 2-118 in an 
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80% yield. Disappointingly, the 2° alcohol could not be oxidized back to the ketone 
despite extensive efforts, as only ring expansion products 2-119 and 2-120 were observed 
(Scheme 2-24).  
 
Scheme 2-24. Synthesis of bicyclic cyclopropane 2-118. 
A plausible mechanism for this ring expansion is shown in Scheme 2-25. Typical 
activation of cyclopropyl alcohol 2-118 (with DMSO shown in this case) results in 2-121. 
Instead of undergoing deprotonation with base to yield ketone 2-74 (Path A), the more 
favorable pathway is ring expansion55 to give 2-122 which eventually deprotonates to 
diene 2-120. Any formation of desired ketone 2-74 quickly undergoes ring expansion to 
yield 1,4-diketone 2-119. 
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Scheme 2-25. Proposed mechanism for the formation of ring expansion products 2-119 
and 2-120. 
 In order to investigate if this ring expansion is solely due to severe ring strain 
associated with medium sized ring, we wanted to examine a macrocycle. Thus, 13-
membered cyclopropyl alcohol 2-123 was prepared using similar steps discussed above.56 
Unfortunately, this compound also resulted in ring expansion products as discussed above 
(Scheme 2-26).  
 
Scheme 2-26. Attempted oxidation of cyclopropyl alcohol 2-123. 
 We then wanted to replace the methoxy functionality with acetoxy, hoping it 
would reduce the electron-density on oxygen, impeding the cyclopropane ring from 
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expanding (see Scheme 2-25). Thus, the cyclotridecane-1,3-dione (2-126) was converted 
into vinylogous anhydride 2-128 using isopropenyl acetate (2-127, Scheme 2-27). 
 
Scheme 2-27. Acetylation of cyclotridecane-1,3-dione (2-126). 
As 2-128 is less electron rich compared to its methoxy analogue, we attempted a 
Corey-Chaykovsky cyclopropanation, and were surprised to isolate thiabenzene l-oxide 
2-131.57 
 
Scheme 2-28. Formation of thiabenzene 1-oxide 2-131. 
 Thiabenzene 1-oxides are known in the literature since the 1960s for their 
appreciable aromatic conjugation,58 and have been used in synthesis of coordination 
complexes.59  
The structure of the thiabenzene 2-131 was assigned based on single crystal X-ray 
diffraction and the ORTEP structure is depicted in Figure 2-7.60 
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Figure 2-7. ORTEP structure of thiabenzene 1-oxide 2-131. 
A plausible mechanism accounting the formation of 2-131 is depicted in Scheme 
2-29. Nucleophilic attack of the in situ generated ylide 2-132 on 2-128 results in 
intermediate 2-133. Which instead of undergoing a ring closure to give cyclopropane 2-
130 (Path A) eliminates acetate to give enone 2-134. Deprotonation of the methyl of the 
sulfoxide followed by 1,2-addition on the carbonyl 2-135 results in intermediate 2-136. 
Protonation of the alkoxide, followed by dehydration and aromatization results in 
thiabenzene 1-oxide 2-131. 
137 
 
 
Scheme 2-29. Proposed mechanism for the formation of thiabenzene 1-oxide 2-131. 
After numerous unsuccessful attempts to oxidize the cyclopropyl alcohols 2-118 
and 2-123 to bicyclic DA cyclopropanes to test our methodology, this route was 
terminated.  
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2.5.2 Progress Towards the Formal Synthesis 
As our initial strategy did not allow us to try our anticipated [3+2] cycloaddition, we 
revised our strategy to make streptorubin B (2-1) via an intramolecular DA 
cyclopropane/nitrile cycloaddition (Scheme 2-30).  
 
Scheme 2-30. Retrosynthesis of streptorubin B (2-1) via an intramolecular DA 
cyclopropane/nitrile cycloaddition. 
 As shown in Scheme 2-30, the target can be achieved from a condensation 
reaction of pyrrolophane 2-52 with known aldehyde 2-72. This has been well established 
by the Thompson group in their enantioselective synthesis (see Scheme 2-10). Thus, we 
chose pyrrolophane 2-52 as a target for our synthesis. Our idea was to proceed through an 
intramolecular cycloaddition of DA cyclopropane/nitrile 2-140. Dealkoxy-carbonylation 
of the ester in 2-139 would result in target molecule 2-52. Intermediate 2-140 is proposed 
to be made from known oxonan-2-one 2-145 (Scheme 2-31). 
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Scheme 2-31. Retrosynthesis of intermediate 2-140. 
 As shown in Scheme 2-31, we anticipated that the nitrile functionality could come 
from an SN2 displacement of mesylated alcohol 2-141.  The DA cyclopropane could 
come from cyclopropanation of enol ether 2-143 with ethyl diazoacetate. Enol ether 2-
143 could be made from a reductive ring opening of lactone 2-144 followed by a Wittig 
reaction of the resulting aldehyde. Ultimately, lactone 2-144 could be generated from a 
base mediated butylation of known oxonan-2-one 2-145. 
 As an intramolecular variant of [3+2] cycloaddition between DA cyclopropanes 
and nitriles is unknown, we thought it would be practical to perform a model study prior 
to our intended late stage [3+2] cycloaddition. Thus, we targeted model compound 2-146, 
which can be prepared from known aldehyde 2-149 via a Wittig reaction, 
cyclopropanation, followed by cyanation of alkyl chloride (2-147, Scheme 2-34).  
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Scheme 2-32. Retrosynthesis for the model compound 2-146. 
 The forward synthesis began with the oxidation of commercially available alcohol 
2-150 to give aldehyde 2-149 (Scheme 2-33). Wittig reaction of the aldehyde 2-149 with 
the ylide in situ generated from 2-151 gave the enol ether 2-148 as a 1:0.7 mixture of E 
and Z isomers in 91% yield. Surprisingly, cyclopropanation of enol ether 2-148 with 
ethyl diazoacetate (2-152) was unsuccessful under either Cu(II) or Rh(II) catalysis. 
 
Scheme 2-33. Attempted synthesis of cyclopropane 2-147. 
 We then converted the alkyl chloride 2-148 to nitrile 2-153 and subjected it to 
cyclopropanation conditions. Disappointingly the cyclopropanation was unsuccessful 
despite a variety of conditions employed. 
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Scheme 2-34. Attempted synthesis of model system 2-146. 
 We hypothesized having an alkyl chloride or nitrile functionality in the molecule 
might be causing the problem in cyclopropanation, and thus we decided to pursue the 
originally proposed strategy towards streptorubin B (see Scheme 2-30 and Scheme 2-31). 
But, unfortunately, due to time constraints this project was suspended. 
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2.6 Conclusions and Outlook 
Unfortunately, we never got to try our anticipated [3+2] cycloaddition of DA 
cyclopropane and nitrile towards the synthesis of streptorubin B.  Herein we described 
the two different strategies investigated towards the synthesis of streptorubin B. Although 
the synthesis was not complete, the described synthesis of bicyclic cyclopropyl alcohols, 
2-118 and 2-123, could potentially be of use for future studies. The proposed formal 
synthesis seems much simpler, but many challenging synthetic steps need to be 
overcome. The intramolecular cycloaddition of DA cyclopropanes/nitriles, if ideally 
executed, could be an efficient way to make pyrrole macrocycles.  
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2.7 Experimental 
2.7.1 General Considerations 
Same as in section 1.4.1.  
2.7.2 Experimental Procedures and Characterization Data 
 
Compound 2-79 
Following literature protocol,61 a three neck round bottom flask (RBF) containing a 
magnetic stir bar was fitted with a Liebig condenser and a pressurized addition funnel. 
The system was flame dried under vacuum and purged with argon twice. Toluene (600 
mL) was charged into the flask through the third neck of the flask followed by pentane 
washed sodium (24.00 g, 1043.93 mmol, 4.8 equiv) in pieces. The solution was refluxed 
for about 1 h to produce a sodium dispersion. The addition funnel was charged with 
toluene (200 mL), dimethyl suberate (50.00 g, 217.10 mmol, 1 equiv), and 
chlorotrimethylsilane (152 mL, 1197.64 mmol, 5.5 equiv). The solution in the addition 
funnel was mixed via argon ebullition and added dropwise over 3 h to the refluxing RM, 
with stirring. The RM turned purple upon addition. After addition, stirring and reflux 
were continued for 16 h. After being cooled to rt, the mixture was vacuum filtered 
through a plug of glass wool and then vacuum filtered through a pad of Celite® (3 cm) 
on a glass frit to remove residual sodium particles (about 200 mL of hexane/s were used 
for washings). The resulting light yellow filtrate was distilled to yield the title compound 
as a colorless oil (31.65 g, 0.11 mol, 51%): bp 92-97 °C/1 mbar. 
Rf = 0.29 (10% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 2.14 - 2.19 (m, 4 H), 1.56 - 1.62 (m, 4 H), 1.49 - 1.54 (m, 
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4 H), 0.18 (s, 18 H). 
13C NMR (151 MHz, CDCl3) δ 133.1, 31.2, 28.8, 26.4, 1.1. 
1H and 13C NMR spectra were in agreement with previously reported data.61  
 
Compound 2-78 
Following literature protocol,36b to a degassed solution of 2-79 (63.30 g, 0.221 mol, 1.0 
equiv) and CH2I2 (159.75 g, 0.596 mol, 2.7 equiv) in toluene (750 mL) at -15 °C, was 
slowly added (over a period of 1 h) a solution of Et2Zn (79.12 g, 0.64 mol, 2.9 equiv)
62 in 
toluene (250 mL). After addition, the RM was stirred for 1 h, then warmed up to rt, and 
stirred for about 16 h. The RM was then cooled to -15 °C and carefully was added a satd. 
NH4Cl aq solution (300 mL). Salts filtered by passing through a pad of Celite® (5 cm) 
and washing with ether (200 mL). Layers separated, and aq layer extracted with ether (2 
x 300 mL). Combined organic extractions were dried over anhyd. MgSO4, filtered, and 
concentrated in vacuo. The resulting pale yellow oil was distilled to yield the title 
compound as a colorless oil (54.00 g, 0.18 mol, 81%): bp 110-115 °C/1 mbar. 
Rf = 0.59 (10% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 2.13 (dt, J = 14.8, 3.7 Hz, 2 H), 1.72 – 1.80 (m, 2 H), 1.57 
– 1.65 (m, 2 H), 1.27 – 1.35 (m, 4 H), 1.09 (ddd, J = 15.1, 13.1, 3.5 Hz, 2 H), 0.76 (d, J = 
6.5 Hz, 1 H), 0.38 (d, J = 6.5 Hz, 1 H), 0.16 (s, 18 H). 
13C NMR (151 MHz, CDCl3) δ 59.9, 34.9, 26.3, 25.5, 24.7, 1.4. 
1H NMR spectrum was in agreement with previously reported data.36b 
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Compound 2-77 
 Following literature protocol,63 to a degassed solution of 2-78 (54.00 g, 0.180 mol, 1.0 
equiv) in DMF (540 mL) at rt, was added anhyd. FeCl3 (64.11 g, 0.395 mol, 2.2 equiv) in 
10 equal portions. After addition, the RM was heated to 60 °C and maintained for 18 h.  
RM then cooled down to rt and transferred into a vigorously stirring aq solution of 1 N 
HCl (500 mL) and stirred for 3 h. RM then extracted with CHCl3 (2 x 500 mL, 2 x 250 
mL), dried over anhyd. MgSO4, and concentrated in vacuo. The crude compound was 
then purified on silica gel flash chromatography (15% EtOAc/hexanes) to afford the title 
compound as a pale brown syrup (19.10 g, 0.12 mol, 69%). 
Rf = 0.28 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 3.68 (s, 2 H), 2.52 – 2.56 (m, 4 H), 1.77 – 1.84 (m, 4 H), 
1.43 – 1.49 (m, 4 H). 
13C NMR (151 MHz, CDCl3) δ 204.9, 61.3, 42.4, 25.1, 23.5. 
1H NMR spectrum was in agreement with previously reported data.63 
 
Compound 2-113 
To a solution of 2-77 (260 mg, 1.69 mmol, 1 equiv) and CH(OMe)3 (197 mg, 1.86 mmol, 
1.1 equiv) in MeOH (1 mL) at rt, was added TsOH·H2O (3 mg, 0.02 mmol, 0.01 equiv). 
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RM was then heated to 50 °C and maintained for 5 h. Cooled down to rt, concentrated in 
vacuo, and the residue was diluted in CH2Cl2 (2 mL) and passed through a plug of silica 
gel and concentrated in vacuo. The crude compound purified on silica gel flash 
chromatography (15% EtOAc/hexanes) to afford the title compound as a color less oil 
(200 mg, 1.07 mmol, 64%). 
Rf = 0.24 (20% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 3.66 (s, 3 H), 2.42 (t, J = 7.3 Hz, 2 H), 2.30 (t, J = 7.6 Hz, 
2 H), 2.13 (s, 3 H), 1.54 – 1.66 (m, 4 H), 1.27 – 1.36 (m, 4 H). 
13C NMR (101 MHz, CDCl3) δ 208.5, 173.7, 51.0, 43.2, 33.6, 29.5, 28.5, 28.4, 24.4, 
23.2. 
1H NMR spectrum was in agreement with previously reported data.64 
 
Compound 2-76 
To a suspension of KH [(30% in mineral oil) 5.20 g, 38.91 mmol, 2 equiv] in a RBF at 0 
°C was slowly added DME (90 mL). To this dark brown RM, was slowly added a 
solution of 2-77 (3.00 g, 19.45 mmol, 1.0 equiv) in DME (10 mL) (syringe pump 
addition, 0.5 mL/min). After addition, the RM stirred at the same temp for about 10 min, 
then warmed up to rt and stirred for 1 h.65 RM then cooled down to 0 °C, at which time a 
fine powder of Me3O·BF4 (5.75 g, 38.90 mmol, 2.0 equiv) was added in 2 equal portions 
with a 5 min interval. After addition, RM was stirred at the same temp for 1 h, and at rt 
for 14 h. Cooled down to 0 °C and carefully was added H2O (30 mL). Warmed up to rt, 
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stirred for 15 min, DME removed in vacuo, and aq layer extracted into EtOAc (50 mL, 2 
x 25 mL). Combined organic extractions were dried over anhyd. MgSO4 and concentrated 
in vacuo. The crude compound was purified on silica gel flash chromatography (0-20% 
EtOAc/hexanes) to afford the title compound as a pale brown oil, which turned into a 
cake upon cooling in the freezer at around -5 °C (2.27 g, 13.49 mmol, 69%). 
Rf = 0.29 (30% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 5.48 (s, 1 H), 3.61 (s, 3 H), 2.72 (dt, J = 9.1, 3.1 Hz, 4 H), 
1.75 – 1.84 (m, 2 H), 1.55 – 1.68 (m, 4 H), 1.44 – 1.52 (m, 2 H). 
13C NMR (101 MHz, CDCl3) δ 203.7, 172.8, 107.3, 55.4, 40.6, 31.2, 29.1, 28.7, 26.7, 
25.0. 
HRMS (m/z): 168.1147 (Calcd for C10H16O2, 168.1150). 
 
Compound 2-117 
Following literature protocol,66 to a suspension of LiAlH4 (1.96 g, 51.65 mmol, 1.1 
equiv) in Et2O (100 mL) at -78 °C was added a solution of 2-76 (7.90 g, 46.96 mmol, 1.0 
equiv) in Et2O (50 mL) over a period of 1 h. After addition, RM stirred at the same temp 
for 1 h and carefully was added H2O (3 mL) followed by 10% aq NaOH (2 mL) and 
finally with more H2O (10 mL). RM then warmed up to rt and stirred until the RM turned 
into a white slurry. Salts filtered by passing through a pad of Celite® (3 cm) washing 
with Et2O (20 mL). Et2O dried over anhyd. MgSO4 and concentrated in vacuo to afford 
the title compound as a pale yellow syrup (7.50 g, 44.05 mmol, 94%) which was 
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reasonably pure and forwarded to next step without further purification. 
Rf = 0.32 (50% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 4.61 (td, J = 9.0, 4.4 Hz, 1 H), 4.39 (d, J = 8.8 Hz, 1 H), 
3.52 (s, 3 H), 2.23 – 2.30 (m, 1 H), 2.12 – 2.18 (m, 1 H), 1.79 – 1.87 (m, 1 H), 1.67 – 
1.77 (m, 2 H), 1.49 – 1.57 (m, 3 H), 1.41 – 1.49 (m, 3 H), 1.32 – 1.41 (m, 2 H). 
13C NMR (101 MHz, CDCl3) δ 158.3, 101.0, 70.0, 54.4, 37.7, 32.1, 27.2, 27.0, 24.8, 
23.5. 
HRMS (m/z): 170.1308 (Calcd for C10H18O2, 170.1307). 
 
Compound 2-118 
Following literature protocol,67 to a degassed solution of 2-117 (7.50 g, 44.05 mol, 1.0 
equiv) and CH2I2 (35.40 g, 132.16 mol, 3.0 equiv) in toluene (130 mL) at -15 °C, was 
slowly added (over a period of 1 h) a solution of Et2Zn (16.32 g, 132.16 mol, 3.0 equiv) 
in toluene (120 mL). After addition, the RM was stirred for 1 h, then warmed up to rt, and 
stirred for about 18 h. The RM was then cooled to -15 °C and carefully added a half satd. 
NH4Cl aq solution (250 mL). RM warmed up to rt, and stirred for 15 min. Salts filtered 
by passing through a pad of Celite® (5 cm) washing with ether (200 mL). Layers 
separated, and aq layer extracted with ether (2 x 300 mL). Combined organic extractions 
were dried over anhyd. MgSO4 and concentrated in vacuo. The residue was purified on 
silica gel flash chromatography (0-20% EtOAc/hexanes, buffered with 1% Et3N) to 
afford the title compound as a pale yellow syrup (6.50 g, 35.27 mmol, 80%). 
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Rf = 0.19 (50% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 3.41 (td, J = 10.3, 4.1 Hz, 1 H), 3.23 (s, 3 H), 2.56 (ddd, J 
= 15.8, 7.0, 1.2 Hz, 1 H), 1.79 – 1.87 (m, 2 H), 1.65 – 1.77 (m, 2 H), 1.48 – 1.65 (m, 4 
H), 1.33 – 1.41 (m, 1 H), 1.19 – 1.28 (m, 1 H), 1.17 (td, J = 10.1, 6.8 Hz, 1 H), 0.93 (ddd, 
J = 15.8, 10.6, 2.4 Hz, 1 H), 0.88 (dd, J = 10.0, 5.3 Hz, 1 H), 0.16 (dd, J = 7.0, 5.3 Hz, 1 
H). 
13C NMR (101 MHz, CDCl3) δ 72.8, 64.7, 52.8, 37.2, 34.4, 29.6, 27.8, 26.4, 21.6, 20.1, 
13.9. 
HRMS (m/z): 184.1461 (Calcd for C11H20O2, 184.1463). 
 
Compound 2-154 
Following literature protocol,36b a three neck round bottom flask containing a magnetic 
stir bar was fitted with a Liebig condenser and a pressurized addition funnel. The system 
was flame dried under vacuum and purged with argon twice. Xylenes (900 mL) was 
charged into the flask through the third neck of the flask followed by pentane washed 
sodium (24.00 g, 1043.93 mmol, 5.4 equiv) in pieces. The solution was heated to 100 °C 
and maintained for about 1 h to produce a sodium dispersion. The pressurized addition 
funnel was charged with xylenes (300 mL), dimethyl dodecanedioate68 (50.00 g, 193.53 
mmol, 1 equiv), and chlorotrimethylsilane (115.64 g, 1064.41 mmol, 5.5 equiv). The 
solution in the addition funnel was mixed via argon ebullition and then added dropwise 
over 6 h to the RM, with stirring. The RM turned pale brown upon addition. After 
addition, RM heated to reflux and maintained for 4 h before being cooled to rt. The 
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mixture was vacuum filtered through a plug of glass wool and then vacuum filtered 
through a pad of Celite® (3 cm) on a glass frit to remove residual sodium particles (about 
200 mL of hexane/s were used for washings). The resulting brownish yellow filtrate was 
distilled to yield the title compound as a colorless oil (23.50 g, 68.67 mmol, 35%): bp 
125-135 °C/1.5 mbar. 
Rf = 0.29 (10% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 2.09 - 2.12 (t, J = 7.0 Hz, 4 H), 1.52 - 1.57 (m, 4 H), 1.35 
- 1.38 (m, 8 H), 1.26 - 1.32 (m, 4 H), 0.18 (s, 18 H). 
HRMS (m/z): 342.2416 (Calcd for C18H38O2Si2, 342.2410). 
1H spectrum was in agreement with previously reported data.36b 
 
Compound 2-155 
Following literature protocol,36b to a degassed solution of 2-154 (30.00 g, 0.088 mol, 1.0 
equiv) and CH2I2 (63.39 g, 0.268 mol, 2.7 equiv) in toluene (260 mL) at -15 °C, was 
slowly added (over a period of 1 h) a solution of Et2Zn (31.40 g, 0.254 mol, 2.9 equiv) in 
toluene (160 mL). After addition, the RM was stirred for 1 h, then warmed up to rt, and 
stirred for about 12 h. The RM was then cooled to -15 °C and carefully was added a satd. 
aq solution of NH4Cl (300 mL). RM warmed up to rt and stirred for 30 min. Salts filtered 
by passing through a pad of Celite® (5 cm) washing with ether (200 mL). Layers 
separated, and aq layer extracted with ether (2 x 300 mL). Combined organic extractions 
were dried over anhyd. MgSO4 and concentrated in vacuo to afford the title compound as 
a pale yellow oil in reasonable purity (31.00 g, 0.087 mol, 98% crude yield). The crude 
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compound was directly forwarded to next step without further purification. 
1H NMR (600 MHz, CDCl3) δ 1.77 – 1.87 (m, 4 H), 1.20 – 1.64 (m, 16 H), 0.81 (d, J = 
6.5 Hz, 1 H), 0.44 (d, J = 6.5 Hz, 1 H). 0.17 (s, 18 H). 
1H spectrum was in agreement with previously reported data.36b 
 
Compound 2-126 
 Following literature protocol,36b to a degassed solution of 2-155 (31.00 g, 0.087 mol, 1.0 
equiv) in DMF (300 mL) at rt, was added anhyd. FeCl3 (31.01 g, 0.191 mol, 2.2 equiv) in 
10 equal portions. After addition, RM heated to 60 °C and maintained for 14 h.  RM then 
cooled down to rt and transferred into a vigorously stirring aq solution of 1 N HCl (300 
mL) and stirred for 3 h. RM then extracted with CHCl3 (2 x 200 mL, 2 x 100 mL). 
Combined organic extractions were dried over MgSO4, concentrated in vacuo and the 
residue purified on silica gel flash chromatography (15% EtOAc/hexanes) to afford the 
title compound as a pale brown syrup (0.3:1 mixture of keto, enol tautomers, 16.60 g, 
0.079 mol, 90%). 
Rf = 0.45 (20% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3)  
Signals correspond to keto-tautomer: δ 3.60 (s, 2 H), 2.59 - 2.63 (m, 4 H), 1.66 (dt, J = 
11.9, 6.1 Hz, 4 H), 1.36 (quin, J = 6.6 Hz, 8 H), 1.01 – 110 (m, 4 H). 
Signals correspond to enol-tautomer: δ 5.70 (s, 1 H), 2.26 – 2.31 (m, 4 H), 1.69 – 1.74 
(m, 4 H), 1.20 – 1.32 (m, 12 H). 
1H NMR spectrum was in agreement with previously reported data.63 
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Compound 2-156 
To a solution of 2-126 (3.10 g, 14.74 mmol, 1.0 equiv) and CH(OMe)3 (1.72 g, 16.22 
mmol, 1.1 equiv) in MeOH (15 mL) at 0 °C, was added TsOH·H2O (28 mg, 0.15 mmol, 
0.01 equiv). RM was stirred at the same temp for 1 h, and warmed up to rt. After the RM 
was stirred for 18 h, was carefully added a 15% aq solution of NaOH (0.2 mL), and 
passed through a pad of Celite® washing with Et2O (10 mL). Solvents dried over anhyd. 
MgSO4, concentrated in vacuo, and the residue was purified on silica gel flash 
chromatography (5% EtOAc/hexanes) to afford the title compound as a bright greenish 
yellow oil (1.65 g, 7.35 mmol, 50%). 
Rf = 0.50 (30% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 5.53 (s, 1 H), 3.65 (s, 3 H), 2.88 – 2.94 (m, 2 H), 2.35 – 
2.40 (m, 2 H), 1.71 – 1.79 (m, 2 H), 1.55 – 1.63 (m, 2 H), 1.36 – 1.45 (m, 2 H), 1.16 – 
1.32 (m, 10 H). 
13C NMR (101 MHz, CDCl3) δ 201.8, 175.1, 100.9, 55.2, 45.5, 29.0, 28.0, 27.1, 26.5, 
25.7, 25.5, 24.7, 24.6, 23.7. 
HRMS (m/z): 224.1778 (Calcd for C14H24O2, 224.1776). 
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Compound 2-157 
To a suspension of LiAlH4 (127 mg, 3.35 mmol, 1.0 equiv) in Et2O (9 mL) at -78 °C was 
added a solution of 2-156 (750 mg, 3.34 mmol, 1.0 equiv) in Et2O (4 mL) over a period 
of 30 min. After addition, RM stirred at the same temp for 1.5 h and carefully was added 
H2O (0.5 mL), followed by 10% aq solution of NaOH (0.5 mL), and finally an additional 
H2O (1 mL). RM then warmed up to rt and stirred until the RM turned into a white slurry. 
Salts filtered by passing through a pad of Celite® (2 cm) washing with Et2O (10 mL). 
Et2O dried over anhyd. MgSO4 and concentrated in vacuo to afford the title compound as 
a pale yellow syrup which was carried forward to next step without further purification.69 
Rf = 0.31 (30% EtOAc/hexanes). 
 
Compound 2-123 
To a degassed solution of 2-157 (1.00 g, 4.42 mmol, 1.0 equiv) and CH2I2 (3.20 g, 11.93 
mmol, 2.7 equiv) in toluene (10 mL) at -15 °C, was slowly added (over a period of 1 h) a 
solution of Et2Zn (1.47 g, 11.93 mmol, 2.7 equiv) in toluene (10 mL). After addition, 
stirred the cloudy RM for 30 min, then warmed up to rt, and stirred for about 18 h. The 
RM was then cooled to -15 °C and carefully was added a half satd. aq solution of NH4Cl 
(20 mL), warmed up to rt, and stirred for 5 min. Salts filtered by passing through a pad of 
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Celite® (3 cm) washing with ether (20 mL). Layers separated, and aq layer extracted 
with ether (2 x 15 mL). Combined organic extractions were dried over anhyd. MgSO4 
and concentrated in vacuo. The residue was purified on silica gel flash chromatography 
(0-20% EtOAc/hexanes, buffered with 1% Et3N) to afford the title compound as an off 
white paste (350 mg, 1.46 mmol, 33% from crude 2-124). 
Rf = 0.43 (50% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 3.22 (s, 3 H), 3.14 (td, J = 9.7, 1.8 Hz, 1 H), 2.30 (ddd, J 
= 15.0, 11.5, 5.5 Hz, 1 H), 1.77 – 1.85 (m, 1 H), 1.58 – 1.65 (m, 2 H), 1.38 – 1.57 (m, 6 
H), 1.27 – 1.38 (m, 8 H), 1.17 – 1.27 (m, 3 H), 1.00 – 1.06 (m, 1 H), 0.90 (dd, J = 10.3, 
5.6 Hz, 1 H), 0.33 (dd, J = 7.0, 5.3 Hz, 1 H). 
13C NMR (101 MHz, CDCl3) δ 72.2, 65.8, 53.0, 36.1, 33.1, 29.6, 27.0, 25.5, 25.5, 25.2, 
25.0, 24.4, 24.4, 23.5, 15.4. 
HRMS (m/z): 240.2082 (Calcd for C15H28O2, 240.2089). 
 
Compound 2-124 
Following literature protocol,70 to a solution of (COCl)2 (158 mg, 1.25 mmol, 1.5 equiv) 
in CH2Cl2 (4 mL) at -78 °C was added dropwise, a solution of DMSO (162 mg, 2.07 
mmol, 2.5 equiv) in CH2Cl2 (1 mL). The RM was stirred for 10 min, then a solution of 2-
123 (200 mg, 0.83 mmol, 1.0 equiv) in CH2Cl2 (1 mL) was added dropwise (syringe 
pump addition, 0.05 mL/min). After addition, the RM was stirred for 30 min, then Et3N 
(420 mg, 4.15 mmol, 5.0 equiv) was slowly added. Stirring continued for an additional 15 
min, warmed up to rt, and H2O (10 mL) was added. Layers separated, aq layer extracted 
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with CH2Cl2 (2 x 10 mL), combined organic extractions were dried over anhyd. MgSO4, 
and concentrated in vacuo. The residue was purified on silica gel flash chromatography 
(0-15% EtOAc/hexanes, buffered with 1% Et3N) to afford the title compound as a pale 
yellow oil (52 mg, 0.23 mmol, 28%). 
Rf = 0.78 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 6.17 (app ddt, J = 15.1, 10.6, 1.3 Hz, 1 H), 5.33 (d, J = 
10.6 Hz, 1 H), 5.28 (dt, J = 15.0, 7.2 Hz, 1 H), 3.55 (s, 3 H), 2.31 – 2.35 (m, 2 H), 2.16 
(app dq, J =7.1, 1.2 Hz, 2 H), 1.54 - 1.60 (m, 2 H), 1.43 – 1.49 (m, 2 H), 1.34 – 1.39 (m, 
2 H), 1.18 – 1.31 (m, 10 H). 
13C NMR (101 MHz, CDCl3) δ 157.8, 127.7, 126.3, 99.9, 54.2, 30.3, 27.4, 27.2, 26.5, 
26.2, 26.0, 25.6, 25.1, 23.7, 23.1. 
 
Compound 2-125 
The title compound was isolated along with 2-124 as an off white paste (25 mg, 0.11 
mmol, 13%). 
Rf = 0.42 (30% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 2.71 (s, 4 H), 2.48 (t, J = 6.3 Hz, 4 H), 1.66 (quin, J = 6.3 
Hz, 4 H), 1.31 - 1.22 (m, 8 H), 1.18 - 1.12 (m, 4 H). 
1H NMR spectrum was in agreement with previously reported data.71 
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Compound 2-128 
Following literature protocol,72 to a mixture of 2-126 (470 mg, 2.24 mmol, 1 equiv) and 
isopropenyl acetate (2-127, 1.57 g, 15.64 mmol, 7 equiv) at rt was added a few crystals of 
TsOH·H2O. RM was then heated to reflux and maintained for 2 h. Cooled to rt, diluted 
with CH2Cl2 (15 mL), and washed with ice cold Satd. aq solution of NaHCO3. Combined 
organic extractions were dried over anhyd. MgSO4, and concentrated in vacuo. The 
resulting purple syrup was purified on silica gel flash chromatography (10% 
EtOAc/hexanes) to afford the title compound as a yellow syrup (254 mg, 1.07 mmol, 
45%). 
Rf = 0.69 (20% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 6.09 (s, 1 H), 2.34 (s, br, 4 H), 2.26 (s, br, 3 H), 1.67 (s, 
br, 4 H), 1.34 (s, br, 12 H). 
HRMS (m/z): 252.1721 (Calcd for C15H24O3, 252.1725). 
 
Compound 2-131 
To a slurry of Me3SOI (156 mg, 0.71 mmol, 1.2 equiv) in DMSO (1 mL) at rt was added 
NaH (60% w/w in mineral oil, 35 mg, 0.88 mmol, 1.5 equiv). Stirred the RM for 1 h, then 
a solution of 2-128 (140 mg, 0.59 mmol, 1 equiv) in DMSO (1 mL) was added dropwise. 
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The RM was stirred for an additional 18 h, then H2O (10 mL) was slowly added. RM 
extracted into EtOAc (2 x 15 mL), dried over anhyd. MgSO4, and concentrated in vacuo. 
The resulting yellow oil was purified on silica gel flash chromatography (50% 
EtOAc/hexanes) to afford the title compound as an off white fluffy material (99 mg, 0.37 
mmol, 56%). 
Rf = 0.22 (30% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) δ 5.63 (s, 1 H), 5.29 (s, 2 H), 3.45 (s, 3 H), 2.45 (t, J = 6.5 
Hz, 4 H), 1.61 - 1.71 (m, 4 H), 1.12 - 1.30 (m, 10 H), 1.05 - 1.12 (m, 2 H). 
13C NMR (101 MHz, CDCl3) δ 147.6, 104.9, 83.4, 50.6, 36.7, 27.4, 26.8, 26.2, 25.3. 
 
Compound 2-149 
Following literature protocol,73 to a mixture of 2-150 (11.00 g, 66.80 mmol, 1 equiv) and 
TEMPO (1.05 g, 6.72 mmol, 0.1 equiv) in CH2Cl2 (110 mL) at rt was added BIAB (25.00 
g, 77.62 mmol, 1.2 equiv). Stirred the RM at rt until 2-150 was completely consumed (by 
TLC). The RM was washed with satd. aq solution of Na2S2O3 (100 mL), layers separated, 
and aq layer again extracted with CH2Cl2 (2 x 100 mL). Combined organic extractions 
were washed with satd. aq NaHCO3 (100 mL), dried over MgSO4, and concentrated in 
vacuo. The residue was then purified on silica gel flash chromatography (0-5% 
EtOAc/hexanes) to afford the title compound as a yellow oil (10.32 g, 63.45 mmol, 95%). 
Rf = 0.42 (20% EtOAc/hexanes). 
1H NMR (400 MHz, CDCl3) δ 9.77 (t, J = 1.8 Hz, 1 H), 3.53 (t, J = 6.6 Hz, 2 H), 2.43 
(td, J = 7.3, 1.8 Hz, 2 H), 1.73 – 1.81 (m, 2 H), 1.59 – 1.68 (m, 2 H), 1.40 – 1.49 (m, 2 
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H), 1.32 – 1.37 (m, 4 H). 
1H NMR spectrum was in agreement with previously reported data.73 
 
Compound 2-148 
Following literature protocol,74 to a suspension of the salt 2-151 (6.32 g, 18.44 mmol, 1.2 
equiv) in THF (45 mL) at -78 °C was added a solution of tBuOK (2.25 g, 20.05 mmol, 
1.3 equiv) in THF (10 mL). RM was then slowly warmed up to rt, stirred for 1 h, and 
cooled back to -78 °C. To this cold RM was slowly added, a solution of 2-149 (2.50 g, 
15.37 mmol, 1.0 equiv) in THF (10 mL). After addition, RM slowly warmed up to rt, and 
stirred for 14 h before concentrating in vacuo. The residue was dissolved in Et2O (50 mL) 
and washed with H2O (50 mL). The aq layer was extracted with Et2O (2 x 50 mL), 
combined organic extractions were dried over MgSO4, and concentrated in vacuo. The 
crude compound was then purified on silica gel flash chromatography (0-10% 
EtOAc/hexanes) to afford the title compound as an inseparable mixture of E and Z 
isomers (1.0:0.7; 2.67 g, 14.00 mmol, 91%). 
Rf = 0.56 (15% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3)  
Signals correspond to E-isomer: δ 6.26 (d, J = 12.3 Hz, 1 H), 4.70 (dt, J = 12.6, 7.2 Hz, 1 
H), 3.51 (td, J = 6.8, 1.8, Hz, 2 H), 3.48 (s, 3 H), 1.90 (q, J = 6.8 Hz, 2 H), 1.72 – 1.78 
(m, 2 H), 1.37 – 1.45 (m, 2 H), 1.27 – 1.35 (m, 6 H). 
Signals correspond to Z-isomer: δ 5.84 – 5.86 (m, 1 H), 4.29 – 4.33 (m, 1 H), 3.56 (s, 3 
H), 3.51 (td, J = 6.8, 1.8 Hz, 2 H), 2.01 – 2.07 (m, 2 H), 1.72 – 1.78 (m, 2 H), 1.37 – 1.45 
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(m, 2 H), 1.27 – 1.35 (m, 6 H). 
13C NMR (151 MHz, CDCl3) δ 147.0, 146.0, 106.8, 102.9, 55.8, 45.0, 32.6, 30.6, 29.0, 
28.7, 27.6, 26.8. 
HRMS (m/z): 181.1467 (Calcd for C10H19ClO, 181.1467). 
 
 
Compound 2-153 
Following literature protocol,75 to a mixture of 2-148 (1.18 g, 6.19 mmol, 1 equiv) in 
MeCN (11 mL) at rt, was added NaCN (0.76 g, 15.47 mmol, 2.5 equiv). The RM was 
then heated to 120 °C in a microwave reactor for 16 h. Cooled to rt, filtered through a 
plug of cotton, washed with CH2Cl2 (10 mL), and concentrated in vacuo. The resulting 
residue dissolved in CH2Cl2 (25 mL), washed with H2O (25 mL), and aq layer extracted 
with CH2Cl2 (2 x 25 mL). Combined organic extractions were dried over MgSO4, and 
concentrated in vacuo. The crude compound was then purified on silica gel flash 
chromatography (0-15% EtOAc/hexanes) to afford the title compound as a pale yellow 
oil (0.77 g, 4.25 mmol, 69%). 
Rf = 0.42 (20% EtOAc/hexanes). 
1H NMR (600 MHz, CDCl3) E:Z ; 1.0:0.7. 
Signals correspond to E-isomer: δ 6.27 (d, J =12.3 Hz, 1 H), 4.71 (dt, J = 12.6, 7.5 Hz, 1 
H), 3.50 (s, 3 H), 2.33 (td, J = 7.3, 2.9 Hz, 2 H), 1.91 (q, J = 6.5 Hz, 2 H), 1.65 (quin, J = 
7.3 Hz, 2 H), 1.41 – 1.49 (m, 2 H), 1.26 – 1.38 (m, 6 H). 
Signals correspond to Z-isomer: δ 5.87 (app d, J = 6.5 Hz, 1 H), 4.32 (q, J = 6.8 Hz, 1 H), 
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3.57 (s, 3 H), 2.33 (td, J = 7.3, 2.9 Hz, 2 H), 2.02 – 2.07 (m, 2 H), 1.65 (quin, J = 7.3 Hz, 
2 H), 1.41 – 1.49 (m, 2 H), 1.26 – 1.38 (m, 6 H). 
HRMS (m/z): 181.1467 (Calcd for C11H19NO, 181.1467). 
  
161 
 
2.8 Notes and References 
 
1.  For a comprehensive review on structure, chemical synthesis, and biosynthesis of 
prodigiosins, see: Hu, D. X.; Withall, D. M.; Challis, G. L.; Thomson, R. J. Chem. 
Rev. 2016, 116, 7818. 
2.  For a review on chemistry and biology of prodigiosins, see; (a) Manderville, R. A. 
Curr. Med. Chem. Anti-Cancer Agents 2001, 1, 195. (b) Fürstner, A. Angew. Chem. 
Int. Ed. 2003, 42, 3582. (b) Williamson, N. R.; Fineran, P. C.; Leeper, F. J.; 
Salmond, G. P. C. Nat. Rev. Microbiol. 2006, 4, 887. (c) Williamson, N. R.; Fineran, 
P. C.; Gristwood, T.; Chawrai, S. R.; Leeper, F. J.; Salmond, G. P. C. Future 
Microbiol. 2007, 2, 605. 
3.  For selected examples of biological activity of natural prodigiosins, see: (a) Castro, 
A. J. Nature 1967, 213, 903. (b) Kim, H.; Hayashi, M.; Shibata, Y.; Wataya, Y.; 
Mitamura, T.; Horii, T.; Kawauchi, K.; Hirata, H.; Tsuboi, S.; Moriyama, Y. Biol. 
Pharm. Bull. 1999, 22, 532. (c) Isaka, M.; Jaturapat, A.; Kramyu, J.; Tanticharoen, 
M.; Thebtaranonth, Y. Antimicrob. Agents Chemother. 2002, 46, 1112. (d) Laurent, 
D.; Pietra, F. Mar. Biotechnol. 2006, 8, 433. (e) Papireddy, K.; Smilkstein, M.; 
Kelly, J. X.; Shweta; Salem, S. M.; Alhamadsheh, M.; Haynes, S. W.; Challis, G. L.; 
Reynolds, K. A. J. Med. Chem. 2011, 54, 5296. 
4.  For selected examples of biological activity of natural and synthetic prodigiosins, 
see: (a) Harashima, K.; Tsuchida, N.; Tanaka, T.; Nagasatu, J. Agric. Biol. Chem. 
1967, 31, 481. (b) Nakamura, A.; Nagai, K.; Ando, K.; Tamura, G. J. Antibiot. 1986, 
39, 1155. (c) Tsuji, R. F.; Yamamoto, M.; Nakamura, A.; Katoka, T.; Magae, J.; 
Nagai, K.; Jamasaki, M. J. Antibiot. 1990, 43, 1293. (d) Lee, M.-H.; Yamashita, M.; 
Tsuji, R. F.; Yamasaki, M.; Kataoka, T.; Magae, J.; Nagai, K. J. Antibiot. 1998, 51, 
92. (e) Han, S. B.; Kim, H. M.; Kim, Y. H.; Lee, C. W.; Jang, E-S.; Son, K. H.; Kim, 
S. U.; Kim, Y. K. J. Immunopharmacol. 1998, 20, 1. 
5.  D’Alessio, R.; Bargiotti, A.; Carlini, O.; Colotta, F.; Ferrari, M.; Gnocchi, P.; Isetta, 
A.; Mongelli, N.; Motta, P.; Rossi, A.; Rossi, M.; Tibolla, M.; Vanotti, E. J. Med. 
Chem. 2000, 43, 2557. 
 
162 
 
 
6.  (a) Nguyen, M.; Marcellus, R. C.; Roulston, A.; Watson, M.; Serfass, L.; Murthy 
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